[{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"data","dir":"Articles","previous_headings":"","what":"Data","title":"Adverse Events : Macros SAS","text":"commence par charger la base de données. Ici j’utilise la fonction grstat_example() pour ne pas dépendre de données réelles privées, mais en pratique utiliserait plutôt EDCimport::read_trialmaster(\"path//file.zip\"). s’intéresse à deux datasets : - ae qui contient les données d’adverse events - enrolres qui contient tous les patients et leur bras de traitement.","code":"library(grstat) library(flextable) library(dplyr)  # tm = EDCimport::read_trialmaster(\"path/to/file.zip\") tm = grstat_example() attach(tm)  head(ae) #> # A tibble: 6 × 7 #>   subjid aesoc                                  aeterm  aegr sae   aerel crfname #>    <int> <chr>                                  <chr>  <dbl> <fct> <chr> <chr>   #> 1      1 Psychiatric disorders                  Subst…     1 No    Stan… ae      #> 2      1 Social circumstances                   Cultu…     1 No    Expe… ae      #> 3      1 Pregnancy, puerperium and perinatal c… Fetal…     2 Yes   Canc… ae      #> 4      1 Eye disorders                          Visio…     1 No    Radi… ae      #> 5      1 Cardiac disorders                      Cardi…     2 No    Other ae      #> 6      2 Eye disorders                          Retin…     1 No    Stan… ae  head(enrolres) #> # A tibble: 6 × 5 #>   subjid arm       arm3        date_inclusion crfname  #>    <int> <fct>     <fct>       <date>         <chr>    #> 1      1 Control   Treatment B 2023-01-22     enrolres #> 2      2 Control   Control     2023-03-12     enrolres #> 3      3 Treatment Treatment A 2023-03-30     enrolres #> 4      4 Control   Control     2023-04-03     enrolres #> 5      5 Treatment Treatment A 2023-05-26     enrolres #> 6      6 Treatment Treatment A 2023-06-03     enrolres"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"macro-ae_grades","dir":"Articles","previous_headings":"","what":"Macro AE_grades","title":"Adverse Events : Macros SAS","text":"La macro AE_grades est implémentée dans la fonction ae_table_grade(). Cette fonction retourne des objets de classe crosstable, lesquels ont une méthode as_flextable() qui les transforme en table HTML de classe flextable. Voir la description du package crosstable pour plus d’informations: documentation.  Voir la description du package flextable pour la liste des modificateurs (comme add_footer_lines()) : documentation.","code":""},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_grades1-table-des-grades-maximum-par-patient","dir":"Articles","previous_headings":"Macro AE_grades","what":"AE_grades1 : Table des grades maximum par patient","title":"Adverse Events : Macros SAS","text":"label variable Treatment arm patients (N=200) Patient maximum AE grade declared AE 8 (4%) Grade 1 38 (19%) Grade 2 62 (31%) Grade 3 54 (27%) Grade 4 34 (17%) Grade 5 4 (2%) Percentages reflect proportion patients whose maximum AE grade indicated.","code":"ae_table_grade(df_ae=ae, df_enrol=enrolres, arm=NULL, variant=\"max\") %>%    as_flextable(header_show_n=TRUE) %>%    add_footer_lines(\"Percentages reflect the proportion of patients whose maximum AE grade was as indicated.\")"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_grades2-table-des-grades-maximum-par-patient-stratifié-sur-le-bras","dir":"Articles","previous_headings":"Macro AE_grades","what":"AE_grades2 : Table des grades maximum par patient stratifié sur le bras","title":"Adverse Events : Macros SAS","text":"pourrait retrouver exactement la sortie SAS en mettant total=FALSE. label variable Treatment arm Total Control (N=100) Treatment (N=100) Patient maximum AE grade declared AE 3 (3%) 5 (5%) 8 (4%) Grade 1 23 (23%) 15 (15%) 38 (19%) Grade 2 32 (32%) 30 (30%) 62 (31%) Grade 3 27 (27%) 27 (27%) 54 (27%) Grade 4 13 (13%) 21 (21%) 34 (17%) Grade 5 2 (2%) 2 (2%) 4 (2%) Percentages reflect proportion patients presenting one AE given grade","code":"ae_table_grade(df_ae=ae, df_enrol=enrolres, arm=\"arm\", variant=\"max\") %>%    as_flextable(header_show_n=TRUE) %>%    add_footer_lines(\"Percentages reflect the proportion of patients presenting at most one AE of given grade\")"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_grades3-table-de-tous-les-grades-pour-chaque-patient","dir":"Articles","previous_headings":"Macro AE_grades","what":"AE_grades3 : Table de tous les grades pour chaque patient","title":"Adverse Events : Macros SAS","text":"label variable Treatment arm patients (N=200) Patient least one AE grade declared AE 8 (4%) Grade 1 164 (82%) Grade 2 110 (55%) Grade 3 62 (31%) Grade 4 36 (18%) Grade 5 4 (2%) Percentages reflect proportion patients presenting least one AE given grade","code":"ae_table_grade(df_ae=ae, df_enrol=enrolres, arm=NULL, variant=\"eq\") %>%    as_flextable(header_show_n=TRUE) %>%    add_footer_lines(\"Percentages reflect the proportion of patients presenting at least one AE of given grade\")"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_grades3bis-table-de-tous-les-grades-pour-chaque-patient-stratifié-sur-le-bras","dir":"Articles","previous_headings":"Macro AE_grades","what":"AE_grades3bis : Table de tous les grades pour chaque patient, stratifié sur le bras","title":"Adverse Events : Macros SAS","text":"pourrait retrouver exactement la sortie SAS en mettant total=FALSE. label variable Treatment arm Total Control (N=100) Treatment (N=100) Patient least one AE grade declared AE 3 (3%) 5 (5%) 8 (4%) Grade 1 85 (85%) 79 (79%) 164 (82%) Grade 2 59 (59%) 51 (51%) 110 (55%) Grade 3 30 (30%) 32 (32%) 62 (31%) Grade 4 14 (14%) 22 (22%) 36 (18%) Grade 5 2 (2%) 2 (2%) 4 (2%) Percentages reflect proportion patients presenting least one AE given grade","code":"ae_table_grade(df_ae=ae, df_enrol=enrolres, arm=\"arm\", variant=\"eq\") %>%    as_flextable(header_show_n=TRUE) %>%    add_footer_lines(\"Percentages reflect the proportion of patients presenting at least one AE of given grade\")"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_grades4-table-des-grades-maximum-par-patient-filtrée-sur-les-sae","dir":"Articles","previous_headings":"Macro AE_grades","what":"AE_grades4 : Table des grades maximum par patient, filtrée sur les SAE","title":"Adverse Events : Macros SAS","text":"Il suffit de filtrer la table ae en amont et d’indiquer que le label doit être “SAE”. label variable Treatment arm patients (N=200) Patient maximum SAE grade declared SAE 144 (72%) Grade 1 17 (8%) Grade 2 16 (8%) Grade 3 11 (6%) Grade 4 11 (6%) Grade 5 1 (0%) Percentages reflect proportion patients whose maximum SAE grade indicated.","code":"ae %>%    filter(sae==\"Yes\") %>%    ae_table_grade(df_enrol=enrolres, arm=NULL, variant=\"max\", ae_label=\"SAE\") %>%    as_flextable(header_show_n=TRUE) %>%    add_footer_lines(\"Percentages reflect the proportion of patients whose maximum SAE grade was as indicated.\")"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"macro-ae_soc","dir":"Articles","previous_headings":"","what":"Macro AE_SOC","title":"Adverse Events : Macros SAS","text":"La macro AE_SOC est implémentée dans la fonction ae_table_soc(). Cette fonction retourne des objets de classe ae_table_soc. Ils ont également une méthode as_flextable qui les transforme en table HTML de classe flextable, mais différente de celle de crosstable. Voir ?as_flextable.ae_table_soc pour plus d’informations: lien.  Voir la description du package flextable pour la liste des modificateurs (comme add_footer_lines()) : documentation. Astuce: Pour les sorties sur officer, comme ces tables sont très larges, pensez bien à basculer en format paysage en utilisant officer::body_end_section_continuous(), puis officer::body_end_section_landscape() pour revenir au format portrait.","code":""},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_soc1-table-des-grades-par-soc","dir":"Articles","previous_headings":"Macro AE_SOC","what":"AE_SOC1 : Table des grades par soc","title":"Adverse Events : Macros SAS","text":"peut ajouter total=FALSE pour retirer la colonne “Tot”.  patients (N=200) CTCAE SOC G1 G2 G3 G4 G5 NA Tot Blood lymphatic system disorders 3 (2%) 3 (2%) 3 (2%) 1 (0%)   10 (5%) Cardiac disorders 11 (6%) 4 (2%) 7 (4%) 4 (2%)   26 (13%) Congenital, familial genetic disorders 23 (12%) 10 (5%) 4 (2%) 5 (2%)   42 (21%) Ear labyrinth disorders 7 (4%) 7 (4%) 4 (2%)    18 (9%) Endocrine disorders 11 (6%) 2 (1%) 2 (1%) 1 (0%)   16 (8%) Eye disorders 21 (10%) 16 (8%) 9 (4%) 3 (2%)   49 (24%) Gastrointestinal disorders 5 (2%) 1 (0%)  1 (0%)   7 (4%) General disorders administration site conditions 2 (1%) 5 (2%) 2 (1%)    9 (4%) Hepatobiliary disorders 17 (8%) 8 (4%) 1 (0%) 2 (1%)   28 (14%) Immune system disorders 15 (8%) 9 (4%) 7 (4%) 3 (2%)   34 (17%) Infections infestations 10 (5%) 3 (2%) 1 (0%)  1 (0%)  15 (8%) Injury, poisoning procedural complications 17 (8%) 13 (6%) 3 (2%) 2 (1%)   35 (18%) Investigations 7 (4%) 1 (0%) 3 (2%)    11 (6%) Metabolism nutrition disorders 8 (4%) 2 (1%)     10 (5%) Musculoskeletal connective tissue disorders 5 (2%) 3 (2%) 4 (2%) 1 (0%) 2 (1%)  15 (8%) Neoplasms benign, malignant, unspecified 12 (6%) 12 (6%) 4 (2%) 2 (1%)   30 (15%) Nervous system disorders 5 (2%) 6 (3%)  1 (0%)   12 (6%) Pregnancy, puerperium perinatal conditions 14 (7%) 12 (6%) 4 (2%) 3 (2%)   33 (16%) Psychiatric disorders 10 (5%) 2 (1%) 3 (2%) 1 (0%)   16 (8%) Renal urinary disorders 5 (2%)  1 (0%) 1 (0%)   7 (4%) Reproductive system breast disorders 3 (2%) 2 (1%) 2 (1%)    7 (4%) Respiratory, thoracic mediastinal disorders 11 (6%) 6 (3%) 5 (2%) 1 (0%) 1 (0%)  24 (12%) Skin subcutaneous tissue disorders 6 (3%) 3 (2%)  1 (0%)   10 (5%) Social circumstances 27 (14%) 12 (6%) 6 (3%) 4 (2%)   49 (24%) Surgical medical procedures 13 (6%) 10 (5%) 4 (2%) 1 (0%)   28 (14%) Vascular disorders 10 (5%) 3 (2%) 1 (0%) 2 (1%)   16 (8%) Declared AE      8 (4%) 8 (4%) header, N represents number patients. Percentages reflect proportion patients whose maximum AE grade indicated.","code":"ae_table_soc(df_ae=ae, df_enrol=enrolres, arm=NULL, term=NULL,               sort_by_count=FALSE) %>%    as_flextable() %>%    add_footer_lines(\"In the header, N represents the number of patients.\") %>%    add_footer_lines(\"Percentages reflect the proportion of patients whose maximum AE grade was as indicated.\")"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_soc2-table-des-grades-par-soc-et-termes","dir":"Articles","previous_headings":"Macro AE_SOC","what":"AE_SOC2 : Table des grades par soc et termes","title":"Adverse Events : Macros SAS","text":"patients (N=200) CTCAE SOC CTCAE v4.0 Term G1 G2 G3 G4 G5 NA Tot Blood lymphatic system disorders Bone marrow disorders    1 (0%)   1 (0%) Coagulation bleeding analyses   1 (0%)    1 (0%) Hematologic neoplasms   1 (0%)    1 (0%) Red blood cell disorders 3 (2%) 3 (2%) 1 (0%)    7 (4%) Cardiac disorders Cardiac arrhythmias 5 (2%) 2 (1%) 1 (0%) 1 (0%)   9 (4%) Cardiac valve disorders 3 (2%) 1 (0%) 5 (2%) 2 (1%)   11 (6%) Coronary artery disorders 3 (2%)   1 (0%)   4 (2%) Heart failures 2 (1%) 1 (0%) 1 (0%)    4 (2%) Congenital, familial genetic disorders Chromosomal abnormalities 5 (2%) 2 (1%) 2 (1%) 3 (2%)   12 (6%) Congenital nervous system disorders 10 (5%) 4 (2%)     14 (7%) Familial hematologic disorders 5 (2%) 2 (1%)  1 (0%)   8 (4%) Hereditary connective tissue disorders 8 (4%) 2 (1%) 2 (1%) 1 (0%)   13 (6%) Ear labyrinth disorders Hearing disorders 2 (1%) 1 (0%) 1 (0%)    4 (2%) Labyrinth disorders 1 (0%) 2 (1%) 1 (0%)    4 (2%) Tinnitus 2 (1%) 2 (1%) 2 (1%)    6 (3%) Vertigo balance disorders 2 (1%) 2 (1%)     4 (2%) Endocrine disorders Adrenal gland disorders 3 (2%)      3 (2%) Parathyroid gland disorders 3 (2%)      3 (2%) Pituitary gland disorders 4 (2%) 1 (0%)     5 (2%) Thyroid gland disorders 2 (1%) 1 (0%) 2 (1%) 1 (0%)   6 (3%) Eye disorders Corneal disorders 8 (4%) 3 (2%) 1 (0%)    12 (6%) Eyelid disorders 5 (2%) 3 (2%) 2 (1%)    10 (5%) Retinal disorders 6 (3%) 6 (3%) 4 (2%) 2 (1%)   18 (9%) Vision disorders 6 (3%) 4 (2%) 2 (1%) 1 (0%)   13 (6%) Gastrointestinal disorders Esophageal disorders 1 (0%)   1 (0%)   2 (1%) Gastric disorders 2 (1%)      2 (1%) Intestinal disorders 2 (1%) 1 (0%)     3 (2%) General disorders administration site conditions General physical health deterioration  3 (2%)     3 (2%) Injection site reactions 1 (0%) 1 (0%) 2 (1%)    4 (2%) Pain discomfort 1 (0%) 1 (0%)     2 (1%) Hepatobiliary disorders Bile duct disorders 4 (2%) 4 (2%)  1 (0%)   9 (4%) Gallbladder disorders 4 (2%) 1 (0%)  1 (0%)   6 (3%) Hepatic failure 5 (2%) 2 (1%)     7 (4%) Liver disorders 6 (3%) 1 (0%) 1 (0%)    8 (4%) Immune system disorders Autoimmune disorders 3 (2%) 1 (0%) 1 (0%) 1 (0%)   6 (3%) Hypersensitivity conditions 7 (4%) 4 (2%) 2 (1%) 1 (0%)   14 (7%) Immunodeficiency 2 (1%) 2 (1%) 2 (1%)    6 (3%) Inflammatory responses 4 (2%) 4 (2%) 2 (1%) 1 (0%)   11 (6%) Infections infestations Bacterial infectious disorders 2 (1%)      2 (1%) Fungal infectious disorders 1 (0%)    1 (0%)  2 (1%) Parasitic infectious disorders 5 (2%) 2 (1%) 1 (0%)    8 (4%) Viral infectious disorders 3 (2%) 1 (0%)     4 (2%) Injury, poisoning procedural complications Poisonings 4 (2%) 4 (2%) 1 (0%)    9 (4%) Procedural complications 12 (6%) 1 (0%) 2 (1%) 1 (0%)   16 (8%) Radiation-related toxicities 2 (1%) 4 (2%)  1 (0%)   7 (4%) Traumatic injuries 3 (2%) 4 (2%)     7 (4%) Investigations Blood analyses 2 (1%)  1 (0%)    3 (2%) Cardiovascular assessments 2 (1%)  1 (0%)    3 (2%) Imaging studies  1 (0%) 1 (0%)    2 (1%) Liver function analyses 3 (2%)      3 (2%) Metabolism nutrition disorders Fluid electrolyte disorders 2 (1%)      2 (1%) Lipid metabolism disorders 3 (2%)      3 (2%) Nutritional disorders 2 (1%) 1 (0%)     3 (2%) Vitamin deficiencies 2 (1%) 1 (0%)     3 (2%) Musculoskeletal connective tissue disorders Arthritis joint disorders  2 (1%)   1 (0%)  3 (2%) Bone disorders  1 (0%) 2 (1%)  1 (0%)  4 (2%) Connective tissue disorders 3 (2%)  1 (0%) 1 (0%)   5 (2%) Muscle disorders 2 (1%)  1 (0%)    3 (2%) Neoplasms benign, malignant, unspecified Benign neoplasms 4 (2%) 7 (4%) 1 (0%) 1 (0%)   13 (6%) Malignant neoplasms 2 (1%) 1 (0%)     3 (2%) Neoplasms unspecified 1 (0%) 2 (1%) 2 (1%)    5 (2%) Tumor progression 5 (2%) 3 (2%) 1 (0%) 1 (0%)   10 (5%) Nervous system disorders Headache disorders 3 (2%) 1 (0%)  1 (0%)   5 (2%) Neurological disorders central nervous system 1 (0%) 2 (1%)     3 (2%) Peripheral neuropathies  2 (1%)     2 (1%) Seizure disorders 2 (1%) 1 (0%)     3 (2%) Pregnancy, puerperium perinatal conditions Breastfeeding issues 3 (2%) 2 (1%)     5 (2%) Fetal complications 2 (1%) 7 (4%) 1 (0%) 2 (1%)   12 (6%) Labor delivery complications 6 (3%) 1 (0%) 2 (1%) 1 (0%)   10 (5%) Pregnancy complications 4 (2%) 2 (1%) 1 (0%)    7 (4%) Psychiatric disorders Anxiety disorders 2 (1%) 2 (1%) 1 (0%)    5 (2%) Mood disorders 2 (1%)  2 (1%)    4 (2%) Sleep disorders 4 (2%)   1 (0%)   5 (2%) Substance-related disorders 3 (2%)      3 (2%) Renal urinary disorders Bladder disorders    1 (0%)   1 (0%) Kidney disorders 2 (1%)      2 (1%) Urethral disorders 1 (0%)  1 (0%)    2 (1%) Urinary tract disorders 2 (1%)      2 (1%) Reproductive system breast disorders Breast disorders   1 (0%)    1 (0%) Female reproductive disorders 1 (0%)  1 (0%)    2 (1%) Male reproductive disorders 1 (0%) 2 (1%)     3 (2%) Menstrual disorders 1 (0%)      1 (0%) Respiratory, thoracic mediastinal disorders Lung function disorders 2 (1%) 2 (1%) 3 (2%)    7 (4%) Pleural disorders 3 (2%)  1 (0%)  1 (0%)  5 (2%) Pulmonary vascular disorders 5 (2%) 1 (0%)  1 (0%)   7 (4%) Respiratory infections 2 (1%) 3 (2%) 2 (1%)    7 (4%) Skin subcutaneous tissue disorders Dermatitis 2 (1%) 1 (0%)     3 (2%) Skin subcutaneous tissue injuries 1 (0%) 1 (0%)     2 (1%) Skin infections 2 (1%)      2 (1%) Skin pigmentation disorders 1 (0%) 1 (0%)  1 (0%)   3 (2%) Social circumstances Cultural issues 11 (6%) 3 (2%) 3 (2%) 2 (1%)   19 (10%) Economic conditions affecting care 2 (1%) 4 (2%)  1 (0%)   7 (4%) Family support issues 14 (7%) 4 (2%) 2 (1%)    20 (10%) Social environmental issues 7 (4%) 2 (1%) 2 (1%) 1 (0%)   12 (6%) Surgical medical procedures Device implantation procedures 5 (2%) 1 (0%) 1 (0%)    7 (4%) Diagnostic procedures 3 (2%) 3 (2%) 1 (0%)    7 (4%) Surgical complications 3 (2%) 3 (2%) 2 (1%)    8 (4%) Therapeutic procedures 3 (2%) 3 (2%) 1 (0%) 1 (0%)   8 (4%) Vascular disorders Hypertension-related conditions  2 (1%) 1 (0%)    3 (2%) Hypotension-related conditions 3 (2%)      3 (2%) Vascular hemorrhagic disorders 5 (2%)   1 (0%)   6 (3%) Venous thromboembolic events 2 (1%) 1 (0%)  1 (0%)   4 (2%) Declared AE       8 (4%) 8 (4%) header, N represents number patients. Percentages reflect proportion patients whose maximum AE grade indicated.","code":"ae_table_soc(df_ae=ae, df_enrol=enrolres, arm=NULL, term=\"aeterm\",               sort_by_count=FALSE) %>%    as_flextable() %>%    add_footer_lines(\"In the header, N represents the number of patients.\") %>%    add_footer_lines(\"Percentages reflect the proportion of patients whose maximum AE grade was as indicated.\")"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_soc3-table-des-grades-par-termes-uniquement-filtrée-sur-les-sae","dir":"Articles","previous_headings":"Macro AE_SOC","what":"AE_SOC3 : Table des grades par termes uniquement, filtrée sur les SAE","title":"Adverse Events : Macros SAS","text":"Il suffit de filtrer la table AE en amont.  patients (N=200) CTCAE SOC G1 G2 G3 G4 G5 NA Tot Blood lymphatic system disorders   1 (0%) 1 (0%)   2 (1%) Cardiac disorders  1 (0%) 2 (1%) 1 (0%)   4 (2%) Congenital, familial genetic disorders 3 (2%) 3 (2%)  1 (0%)   7 (4%) Endocrine disorders   1 (0%) 1 (0%)   2 (1%) Eye disorders  2 (1%) 1 (0%)    3 (2%) Gastrointestinal disorders 2 (1%)   1 (0%)   3 (2%) Hepatobiliary disorders 1 (0%)   1 (0%)   2 (1%) Immune system disorders 3 (2%)   1 (0%)   4 (2%) Injury, poisoning procedural complications  2 (1%)     2 (1%) Investigations 1 (0%)      1 (0%) Metabolism nutrition disorders 1 (0%)      1 (0%) Musculoskeletal connective tissue disorders   1 (0%)    1 (0%) Neoplasms benign, malignant, unspecified 1 (0%) 2 (1%) 1 (0%)    4 (2%) Pregnancy, puerperium perinatal conditions 1 (0%) 5 (2%)  1 (0%)   7 (4%) Psychiatric disorders   1 (0%)    1 (0%) Renal urinary disorders   1 (0%)    1 (0%) Respiratory, thoracic mediastinal disorders    1 (0%) 1 (0%)  2 (1%) Skin subcutaneous tissue disorders 1 (0%) 1 (0%)     2 (1%) Social circumstances 2 (1%) 2 (1%) 1 (0%) 1 (0%)   6 (3%) Surgical medical procedures 2 (1%) 1 (0%) 1 (0%) 1 (0%)   5 (2%) Vascular disorders   1 (0%) 1 (0%)   2 (1%) Declared AE      144 (72%) 144 (72%) header, N represents number patients. Percentages reflect proportion patients whose maximum SAE grade indicated.","code":"ae %>%    filter(sae==\"Yes\") %>%   ae_table_soc(df_enrol=enrolres, term=NULL, arm=NULL, sort_by_count=FALSE) %>%    as_flextable() %>%    add_footer_lines(c(\"In the header, N represents the number of patients.\",                      \"Percentages reflect the proportion of patients whose maximum SAE grade was as indicated.\"))"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_soc45-table-des-grades-stratifiée-sur-le-bras-sans-colonne-total","dir":"Articles","previous_headings":"Macro AE_SOC","what":"AE_SOC4/5 : Table des grades stratifiée sur le bras (sans colonne total)","title":"Adverse Events : Macros SAS","text":"peut ajouter total=FALSE pour retirer la colonne “Tot” et obtenir la sortie AE_SOC5.  Control (N=100) Treatment (N=100) CTCAE SOC G1 G2 G3 G4 G5 NA Tot G1 G2 G3 G4 G5 NA Tot Blood lymphatic system disorders  1 (1%) 1 (1%) 1 (1%)   3 (3%) 3 (3%) 2 (2%) 2 (2%)    7 (7%) Cardiac disorders 7 (7%) 3 (3%) 4 (4%)    14 (14%) 4 (4%) 1 (1%) 3 (3%) 4 (4%)   12 (12%) Congenital, familial genetic disorders 10 (10%) 7 (7%) 2 (2%) 1 (1%)   20 (20%) 13 (13%) 3 (3%) 2 (2%) 4 (4%)   22 (22%) Ear labyrinth disorders 4 (4%) 2 (2%) 2 (2%)    8 (8%) 3 (3%) 5 (5%) 2 (2%)    10 (10%) Endocrine disorders 9 (9%)  1 (1%) 1 (1%)   11 (11%) 2 (2%) 2 (2%) 1 (1%)    5 (5%) Eye disorders 14 (14%) 11 (11%) 4 (4%) 2 (2%)   31 (31%) 7 (7%) 5 (5%) 5 (5%) 1 (1%)   18 (18%) Gastrointestinal disorders 2 (2%) 1 (1%)  1 (1%)   4 (4%) 3 (3%)      3 (3%) General disorders administration site conditions  4 (4%) 2 (2%)    6 (6%) 2 (2%) 1 (1%)     3 (3%) Hepatobiliary disorders 9 (9%) 3 (3%)  2 (2%)   14 (14%) 8 (8%) 5 (5%) 1 (1%)    14 (14%) Immune system disorders 8 (8%) 4 (4%) 4 (4%) 2 (2%)   18 (18%) 7 (7%) 5 (5%) 3 (3%) 1 (1%)   16 (16%) Infections infestations 8 (8%) 3 (3%)     11 (11%) 2 (2%)  1 (1%)  1 (1%)  4 (4%) Injury, poisoning procedural complications 12 (12%) 8 (8%) 1 (1%) 1 (1%)   22 (22%) 5 (5%) 5 (5%) 2 (2%) 1 (1%)   13 (13%) Investigations 5 (5%) 1 (1%) 1 (1%)    7 (7%) 2 (2%)  2 (2%)    4 (4%) Metabolism nutrition disorders 4 (4%) 1 (1%)     5 (5%) 4 (4%) 1 (1%)     5 (5%) Musculoskeletal connective tissue disorders 4 (4%) 2 (2%) 2 (2%) 1 (1%) 2 (2%)  11 (11%) 1 (1%) 1 (1%) 2 (2%)    4 (4%) Neoplasms benign, malignant, unspecified 6 (6%) 7 (7%) 3 (3%) 1 (1%)   17 (17%) 6 (6%) 5 (5%) 1 (1%) 1 (1%)   13 (13%) Nervous system disorders 2 (2%) 3 (3%)     5 (5%) 3 (3%) 3 (3%)  1 (1%)   7 (7%) Pregnancy, puerperium perinatal conditions 7 (7%) 5 (5%) 2 (2%) 2 (2%)   16 (16%) 7 (7%) 7 (7%) 2 (2%) 1 (1%)   17 (17%) Psychiatric disorders 4 (4%) 1 (1%) 1 (1%)    6 (6%) 6 (6%) 1 (1%) 2 (2%) 1 (1%)   10 (10%) Renal urinary disorders 3 (3%)  1 (1%)    4 (4%) 2 (2%)   1 (1%)   3 (3%) Reproductive system breast disorders 1 (1%) 1 (1%) 1 (1%)    3 (3%) 2 (2%) 1 (1%) 1 (1%)    4 (4%) Respiratory, thoracic mediastinal disorders 7 (7%) 3 (3%) 1 (1%)    11 (11%) 4 (4%) 3 (3%) 4 (4%) 1 (1%) 1 (1%)  13 (13%) Skin subcutaneous tissue disorders 2 (2%) 1 (1%)  1 (1%)   4 (4%) 4 (4%) 2 (2%)     6 (6%) Social circumstances 16 (16%) 8 (8%) 3 (3%)    27 (27%) 11 (11%) 4 (4%) 3 (3%) 4 (4%)   22 (22%) Surgical medical procedures 6 (6%) 5 (5%) 2 (2%)    13 (13%) 7 (7%) 5 (5%) 2 (2%) 1 (1%)   15 (15%) Vascular disorders 6 (6%) 1 (1%)     7 (7%) 4 (4%) 2 (2%) 1 (1%) 2 (2%)   9 (9%) Declared AE      3 (3%) 3 (3%)      5 (5%) 5 (5%) header, N represents number patients. Percentages reflect proportion patients whose maximum AE grade indicated.","code":"ae_table_soc(df_ae=ae, df_enrol=enrolres, term=NULL, arm=\"arm\", sort_by_count=FALSE) %>%    as_flextable() %>%    add_footer_lines(\"In the header, N represents the number of patients.\") %>%    add_footer_lines(\"Percentages reflect the proportion of patients whose maximum AE grade was as indicated.\")"},{"path":"https://oncostat.github.io/grstat/articles/adverse_events_sas.html","id":"ae_soc6-table-des-soc-et-termes-tous-grades-confondus-stratifiée-sur-le-bras","dir":"Articles","previous_headings":"Macro AE_SOC","what":"AE_SOC6 : Table des soc et termes tous grades confondus stratifiée sur le bras","title":"Adverse Events : Macros SAS","text":"Control (N=100) Treatment (N=100) CTCAE SOC CTCAE v4.0 Term G1 G2 G3 G4 G5 NA Tot G1 G2 G3 G4 G5 NA Tot Blood lymphatic system disorders Bone marrow disorders    1 (1%)   1 (1%)        Coagulation bleeding analyses   1 (1%)    1 (1%)        Hematologic neoplasms          1 (1%)    1 (1%) Red blood cell disorders  1 (1%)     1 (1%) 3 (3%) 2 (2%) 1 (1%)    6 (6%) Cardiac disorders Cardiac arrhythmias 2 (2%) 2 (2%)     4 (4%) 3 (3%)  1 (1%) 1 (1%)   5 (5%) Cardiac valve disorders 3 (3%) 1 (1%) 4 (4%)    8 (8%)   1 (1%) 2 (2%)   3 (3%) Coronary artery disorders 1 (1%)      1 (1%) 2 (2%)   1 (1%)   3 (3%) Heart failures 1 (1%)      1 (1%) 1 (1%) 1 (1%) 1 (1%)    3 (3%) Congenital, familial genetic disorders Chromosomal abnormalities 2 (2%) 2 (2%) 1 (1%)    5 (5%) 3 (3%)  1 (1%) 3 (3%)   7 (7%) Congenital nervous system disorders 4 (4%) 2 (2%)     6 (6%) 6 (6%) 2 (2%)     8 (8%) Familial hematologic disorders 1 (1%) 1 (1%)     2 (2%) 4 (4%) 1 (1%)  1 (1%)   6 (6%) Hereditary connective tissue disorders 6 (6%) 2 (2%) 1 (1%) 1 (1%)   10 (10%) 2 (2%)  1 (1%)    3 (3%) Ear labyrinth disorders Hearing disorders        2 (2%) 1 (1%) 1 (1%)    4 (4%) Labyrinth disorders 1 (1%) 1 (1%)     2 (2%)  1 (1%) 1 (1%)    2 (2%) Tinnitus 2 (2%)  2 (2%)    4 (4%)  2 (2%)     2 (2%) Vertigo balance disorders 1 (1%) 1 (1%)     2 (2%) 1 (1%) 1 (1%)     2 (2%) Endocrine disorders Adrenal gland disorders 2 (2%)      2 (2%) 1 (1%)      1 (1%) Parathyroid gland disorders 3 (3%)      3 (3%)        Pituitary gland disorders 3 (3%)      3 (3%) 1 (1%) 1 (1%)     2 (2%) Thyroid gland disorders 2 (2%)  1 (1%) 1 (1%)   4 (4%)  1 (1%) 1 (1%)    2 (2%) Eye disorders Corneal disorders 7 (7%) 2 (2%)     9 (9%) 1 (1%) 1 (1%) 1 (1%)    3 (3%) Eyelid disorders 3 (3%) 1 (1%) 1 (1%)    5 (5%) 2 (2%) 2 (2%) 1 (1%)    5 (5%) Retinal disorders 4 (4%) 6 (6%) 3 (3%) 2 (2%)   15 (15%) 2 (2%)  1 (1%)    3 (3%) Vision disorders 4 (4%) 2 (2%)     6 (6%) 2 (2%) 2 (2%) 2 (2%) 1 (1%)   7 (7%) Gastrointestinal disorders Esophageal disorders 1 (1%)   1 (1%)   2 (2%)        Gastric disorders 1 (1%)      1 (1%) 1 (1%)      1 (1%) Intestinal disorders  1 (1%)     1 (1%) 2 (2%)      2 (2%) General disorders administration site conditions General physical health deterioration  2 (2%)     2 (2%)  1 (1%)     1 (1%) Injection site reactions  1 (1%) 2 (2%)    3 (3%) 1 (1%)      1 (1%) Pain discomfort  1 (1%)     1 (1%) 1 (1%)      1 (1%) Hepatobiliary disorders Bile duct disorders 2 (2%) 2 (2%)  1 (1%)   5 (5%) 2 (2%) 2 (2%)     4 (4%) Gallbladder disorders 2 (2%)   1 (1%)   3 (3%) 2 (2%) 1 (1%)     3 (3%) Hepatic failure 4 (4%)      4 (4%) 1 (1%) 2 (2%)     3 (3%) Liver disorders 1 (1%) 1 (1%)     2 (2%) 5 (5%)  1 (1%)    6 (6%) Immune system disorders Autoimmune disorders 2 (2%)      2 (2%) 1 (1%) 1 (1%) 1 (1%) 1 (1%)   4 (4%) Hypersensitivity conditions 5 (5%) 2 (2%) 2 (2%) 1 (1%)   10 (10%) 2 (2%) 2 (2%)     4 (4%) Immunodeficiency  1 (1%)     1 (1%) 2 (2%) 1 (1%) 2 (2%)    5 (5%) Inflammatory responses 1 (1%) 1 (1%) 2 (2%) 1 (1%)   5 (5%) 3 (3%) 3 (3%)     6 (6%) Infections infestations Bacterial infectious disorders 2 (2%)      2 (2%)        Fungal infectious disorders 1 (1%)      1 (1%)     1 (1%)  1 (1%) Parasitic infectious disorders 3 (3%) 2 (2%)     5 (5%) 2 (2%)  1 (1%)    3 (3%) Viral infectious disorders 3 (3%) 1 (1%)     4 (4%)        Injury, poisoning procedural complications Poisonings 4 (4%) 2 (2%)     6 (6%)  2 (2%) 1 (1%)    3 (3%) Procedural complications 7 (7%) 1 (1%) 1 (1%)    9 (9%) 5 (5%)  1 (1%) 1 (1%)   7 (7%) Radiation-related toxicities 2 (2%) 2 (2%)  1 (1%)   5 (5%)  2 (2%)     2 (2%) Traumatic injuries 1 (1%) 3 (3%)     4 (4%) 2 (2%) 1 (1%)     3 (3%) Investigations Blood analyses 2 (2%)  1 (1%)    3 (3%)        Cardiovascular assessments 1 (1%)      1 (1%) 1 (1%)  1 (1%)    2 (2%) Imaging studies  1 (1%)     1 (1%)   1 (1%)    1 (1%) Liver function analyses 2 (2%)      2 (2%) 1 (1%)      1 (1%) Metabolism nutrition disorders Fluid electrolyte disorders        2 (2%)      2 (2%) Lipid metabolism disorders 2 (2%)      2 (2%) 1 (1%)      1 (1%) Nutritional disorders 2 (2%)      2 (2%)  1 (1%)     1 (1%) Vitamin deficiencies  1 (1%)     1 (1%) 2 (2%)      2 (2%) Musculoskeletal connective tissue disorders Arthritis joint disorders  2 (2%)   1 (1%)  3 (3%)        Bone disorders   1 (1%)  1 (1%)  2 (2%)  1 (1%) 1 (1%)    2 (2%) Connective tissue disorders 2 (2%)  1 (1%) 1 (1%)   4 (4%) 1 (1%)      1 (1%) Muscle disorders 2 (2%)      2 (2%)   1 (1%)    1 (1%) Neoplasms benign, malignant, unspecified Benign neoplasms 2 (2%) 5 (5%) 1 (1%) 1 (1%)   9 (9%) 2 (2%) 2 (2%)     4 (4%) Malignant neoplasms  1 (1%)     1 (1%) 2 (2%)      2 (2%) Neoplasms unspecified 1 (1%)  2 (2%)    3 (3%)  2 (2%)     2 (2%) Tumor progression 3 (3%) 2 (2%)     5 (5%) 2 (2%) 1 (1%) 1 (1%) 1 (1%)   5 (5%) Nervous system disorders Headache disorders 3 (3%)      3 (3%)  1 (1%)  1 (1%)   2 (2%) Neurological disorders central nervous system  1 (1%)     1 (1%) 1 (1%) 1 (1%)     2 (2%) Peripheral neuropathies  1 (1%)     1 (1%)  1 (1%)     1 (1%) Seizure disorders  1 (1%)     1 (1%) 2 (2%)      2 (2%) Pregnancy, puerperium perinatal conditions Breastfeeding issues 3 (3%) 2 (2%)     5 (5%)        Fetal complications 1 (1%) 2 (2%)  1 (1%)   4 (4%) 1 (1%) 5 (5%) 1 (1%) 1 (1%)   8 (8%) Labor delivery complications 3 (3%) 1 (1%) 2 (2%) 1 (1%)   7 (7%) 3 (3%)      3 (3%) Pregnancy complications        4 (4%) 2 (2%) 1 (1%)    7 (7%) Psychiatric disorders Anxiety disorders 1 (1%) 1 (1%)     2 (2%) 1 (1%) 1 (1%) 1 (1%)    3 (3%) Mood disorders   1 (1%)    1 (1%) 2 (2%)  1 (1%)    3 (3%) Sleep disorders 1 (1%)      1 (1%) 3 (3%)   1 (1%)   4 (4%) Substance-related disorders 2 (2%)      2 (2%) 1 (1%)      1 (1%) Renal urinary disorders Bladder disorders           1 (1%)   1 (1%) Kidney disorders 2 (2%)      2 (2%)        Urethral disorders   1 (1%)    1 (1%) 1 (1%)      1 (1%) Urinary tract disorders 1 (1%)      1 (1%) 1 (1%)      1 (1%) Reproductive system breast disorders Breast disorders          1 (1%)    1 (1%) Female reproductive disorders   1 (1%)    1 (1%) 1 (1%)      1 (1%) Male reproductive disorders 1 (1%) 1 (1%)     2 (2%)  1 (1%)     1 (1%) Menstrual disorders        1 (1%)      1 (1%) Respiratory, thoracic mediastinal disorders Lung function disorders 2 (2%) 1 (1%)     3 (3%)  1 (1%) 3 (3%)    4 (4%) Pleural disorders 2 (2%)      2 (2%) 1 (1%)  1 (1%)  1 (1%)  3 (3%) Pulmonary vascular disorders 2 (2%) 1 (1%)     3 (3%) 3 (3%)   1 (1%)   4 (4%) Respiratory infections 2 (2%) 1 (1%) 1 (1%)    4 (4%)  2 (2%) 1 (1%)    3 (3%) Skin subcutaneous tissue disorders Dermatitis 2 (2%) 1 (1%)     3 (3%)        Skin subcutaneous tissue injuries        1 (1%) 1 (1%)     2 (2%) Skin infections        2 (2%)      2 (2%) Skin pigmentation disorders    1 (1%)   1 (1%) 1 (1%) 1 (1%)     2 (2%) Social circumstances Cultural issues 7 (7%) 2 (2%) 2 (2%)    11 (11%) 4 (4%) 1 (1%) 1 (1%) 2 (2%)   8 (8%) Economic conditions affecting care  3 (3%)     3 (3%) 2 (2%) 1 (1%)  1 (1%)   4 (4%) Family support issues 9 (9%) 3 (3%)     12 (12%) 5 (5%) 1 (1%) 2 (2%)    8 (8%) Social environmental issues 2 (2%) 1 (1%) 1 (1%)    4 (4%) 5 (5%) 1 (1%) 1 (1%) 1 (1%)   8 (8%) Surgical medical procedures Device implantation procedures 2 (2%)  1 (1%)    3 (3%) 3 (3%) 1 (1%)     4 (4%) Diagnostic procedures 3 (3%) 1 (1%) 1 (1%)    5 (5%)  2 (2%)     2 (2%) Surgical complications 1 (1%) 3 (3%)     4 (4%) 2 (2%)  2 (2%)    4 (4%) Therapeutic procedures 1 (1%) 1 (1%)     2 (2%) 2 (2%) 2 (2%) 1 (1%) 1 (1%)   6 (6%) Vascular disorders Hypertension-related conditions         2 (2%) 1 (1%)    3 (3%) Hypotension-related conditions 2 (2%)      2 (2%) 1 (1%)      1 (1%) Vascular hemorrhagic disorders 2 (2%)      2 (2%) 3 (3%)   1 (1%)   4 (4%) Venous thromboembolic events 2 (2%) 1 (1%)     3 (3%)    1 (1%)   1 (1%) Declared AE       3 (3%) 3 (3%)      5 (5%) 5 (5%) header, N represents number patients. Percentages reflect proportion patients whose maximum AE grade indicated.","code":"ae_table_soc(df_ae=ae, df_enrol=enrolres, arm=\"arm\", term=\"aeterm\",               sort_by_count=FALSE) %>%    as_flextable() %>%    add_footer_lines(\"In the header, N represents the number of patients.\") %>%    add_footer_lines(\"Percentages reflect the proportion of patients whose maximum AE grade was as indicated.\")"},{"path":"https://oncostat.github.io/grstat/articles/kaplan_meier.html","id":"introduction","dir":"Articles","previous_headings":"","what":"Introduction","title":"Kaplan-Meier Guideline Suggestions","text":"example, two key survival endpoints analysed: Progression-Free Survival (PFS): Defined time treatment initiation either disease progression death. Overall Survival (OS): Defined time treatment initiation death cause. vignette covers following steps: Preparation dataset. Creation time--event event indicator variables. Compute Kaplan-meier estimator fitting Kaplan-Meier curves Visualization survival curves accompanied risk tables. approach presented follows recommendations provided Daniel Sjoberg’s ggsurvfit package generating publication-ready Kaplan-Meier plots. First, install packages needed load .","code":"## Load libraries  library(grstat) library(dplyr) library(survival) library(ggsurvfit) library(glue)"},{"path":"https://oncostat.github.io/grstat/articles/kaplan_meier.html","id":"data-overview","dir":"Articles","previous_headings":"Introduction","what":"Data Overview","title":"Kaplan-Meier Guideline Suggestions","text":"dataset used extension dataset provided ggsurvfit package. Additional variables simulated resemble typical dataset oncology clinical study, including information progression status, survival times, treatment characteristics. Note: example, end date determined using pmax() function, selects latest available date following: date death, last visit, last RECIST scan, last patient contact, end treatment, last follow-.","code":"## Display dataset  head(data_surv) #> # A tibble: 6 × 6 #>      id death date_start date_progression date_end   surg                        #>   <dbl> <dbl> <date>     <date>           <date>     <fct>                       #> 1     1     1 2021-04-16 2021-04-18       2021-04-19 Limited Time Since Surgery  #> 2     2     0 2021-05-20 2021-05-25       2021-05-28 Limited Time Since Surgery  #> 3     3     1 2021-03-27 NA               2021-03-28 Limited Time Since Surgery  #> 4     4     1 2021-05-14 NA               2021-05-15 Extended Time Since Surgery #> 5     5     1 2021-05-27 NA               2021-05-28 Extended Time Since Surgery #> 6     6     1 2021-06-06 NA               2021-06-09 Limited Time Since Surgery  dim(data_surv) #> [1] 929   6"},{"path":[]},{"path":"https://oncostat.github.io/grstat/articles/kaplan_meier.html","id":"variable-creation","dir":"Articles","previous_headings":"Data Preparation","what":"Variable Creation","title":"Kaplan-Meier Guideline Suggestions","text":"purpose section create status time variables Progression-Free Survival (PFS) Overall Survival (OS). First, variables time status (indicating whether event occurred censored) need created enable use various functions. Time variable: time variable represents duration defined starting point (e.g., diagnosis, study enrollment, start treatment) time patient’s status recorded (e.g. death, disease progression, recurrence last news). numeric variable measured units days, months, years, depending study’s duration requirements. Status variable: status variable binary, indicating whether event occurred (event = 1) (censored = 0) subject end study period. event (1) indicates subject experienced event interest (e.g., death, relapse, transplant failure, etc.). Censored (0) refers subjects experience event study. individuals, ‘time--event’ considered censored, indicating know experience event certain point.","code":"## Example  data_surv_v2 = data_surv %>%   mutate(     status_PFS = ifelse(!is.na(date_progression), 1, 0 ),     date_status_pfs = pmin(date_progression,date_end, na.rm = TRUE),     status_OS = death,     date_status_OS = date_end,     time_pfs = as.numeric(date_status_pfs-date_start)/30.5,     time_OS = as.numeric(date_status_OS-date_start)/30.5   ) %>%    select(id,time_pfs,time_OS,status_PFS,status_OS,surg)  head(data_surv_v2) #> # A tibble: 6 × 6 #>      id time_pfs time_OS status_PFS status_OS surg                        #>   <dbl>    <dbl>   <dbl>      <dbl>     <dbl> <fct>                       #> 1     1   0.0611  0.0869          1         1 Limited Time Since Surgery  #> 2     2   0.175   0.277           1         0 Limited Time Since Surgery  #> 3     3   0.0487  0.0487          0         1 Limited Time Since Surgery  #> 4     4   0.0220  0.0220          0         1 Extended Time Since Surgery #> 5     5   0.0469  0.0469          0         1 Extended Time Since Surgery #> 6     6   0.0811  0.0811          0         1 Limited Time Since Surgery"},{"path":[]},{"path":"https://oncostat.github.io/grstat/articles/kaplan_meier.html","id":"generate-survival-estimates-using-survfit2","dir":"Articles","previous_headings":"Kaplan-Meier Analysis","what":"Generate survival estimates using survfit2()","title":"Kaplan-Meier Guideline Suggestions","text":"recommend using ggsurvfit package uses survfit2()following syntax:","code":"km.model_PFS = survfit2(Surv(time_pfs, status_PFS) ~ surg, data = data_surv_v2) km.model_PFS #> Call: survfit(formula = Surv(time_pfs, status_PFS) ~ surg, data = data_surv_v2) #>  #>                                    n events median 0.95LCL 0.95UCL #> surg=Limited Time Since Surgery  682    372  0.149   0.141   0.157 #> surg=Extended Time Since Surgery 247    111  0.149   0.141   0.197  # Specific time points can be chosen to extract the estimated survival probabilities and related statistics from the Kaplan-Meier survival model (km.model_PFS). Here, the time points were set at 0.05, 0.10, and 0.20.  tidy_survfit(km.model_PFS, times = c(0.05, 0.10, 0.20)) %>%    select(strata, time, n.risk, n.event, estimate, conf.high, conf.low) #> # A tibble: 6 × 7 #>   strata                       time n.risk n.event estimate conf.high conf.low #>   <fct>                       <dbl>  <dbl>   <dbl>    <dbl>     <dbl>    <dbl> #> 1 Extended Time Since Surgery  0.05    136      60    0.723     0.786    0.665 #> 2 Extended Time Since Surgery  0.1     114       9    0.673     0.741    0.612 #> 3 Extended Time Since Surgery  0.2      39      41    0.403     0.486    0.333 #> 4 Limited Time Since Surgery   0.05    429     156    0.753     0.788    0.720 #> 5 Limited Time Since Surgery   0.1     368      32    0.695     0.733    0.659 #> 6 Limited Time Since Surgery   0.2     101     176    0.337     0.382    0.298"},{"path":"https://oncostat.github.io/grstat/articles/kaplan_meier.html","id":"generate-survival-curves","dir":"Articles","previous_headings":"Kaplan-Meier Analysis","what":"Generate survival curves","title":"Kaplan-Meier Guideline Suggestions","text":"full documentation ggsurvfit, visit ggsurvfit website. cite work, refer following: Sjoberg D, Baillie M, Fruechtenicht C, Haesendonckx S, Treis T (2025). ggsurvfit: Flexible Time--Event Figures. R package version 1.1.0. Available : https://www.danieldsjoberg.com/ggsurvfit/.","code":""},{"path":"https://oncostat.github.io/grstat/articles/kaplan_meier.html","id":"progression-free-survival-pfs","dir":"Articles","previous_headings":"Kaplan-Meier Analysis > Generate survival curves","what":"Progression-Free Survival (PFS)","title":"Kaplan-Meier Guideline Suggestions","text":"plot can customised, example:","code":"km_PFS = survfit2(Surv(time_pfs, status_PFS) ~ surg, data = data_surv_v2) %>%   ggsurvfit(linetype_aes = TRUE) +   add_confidence_interval() +   add_risktable(     risktable_stats = c(\"n.risk\", \"cum.censor\", \"cum.event\" )   ) +   theme_ggsurvfit_KMunicate() +   scale_y_continuous(limits = c(0, 1)) +   scale_x_continuous(expand = c(0.02, 0)) +   theme(legend.position=\"inside\", legend.position.inside = c(0.85, 0.85)) km_PFS N_total <- nrow(data_surv_v2) n_event <- sum(data_surv_v2$status_PFS == 1) title_text <- glue(\"Progression-Free Survival (N={N_total}, n event={n_event})\") km_PFS +   add_censor_mark(size = 4, alpha = 0.4) +   labs(     x = \"Time from beginning of treatment to progression or death (months)\",     y = \"Progression-Free Survival\",     title = title_text   )"},{"path":"https://oncostat.github.io/grstat/articles/kaplan_meier.html","id":"overall-survival-os","dir":"Articles","previous_headings":"Kaplan-Meier Analysis > Generate survival curves","what":"Overall Survival (OS)","title":"Kaplan-Meier Guideline Suggestions","text":"function scale_ggsurvfit() can used automatically adjust axes limits Kaplan-Meier plots better fit data improve visualisation. Note: scale_ggsurvfit() function automatically scales y-axis percentage.","code":"km_OS = survfit2(Surv(time_OS, status_OS) ~ surg, data = data_surv_v2) %>%   ggsurvfit(linetype_aes = TRUE) +   add_confidence_interval() +   add_risktable(     risktable_stats = c(\"n.risk\", \"cum.event\" )   ) +   theme_ggsurvfit_KMunicate() +   scale_ggsurvfit()+   theme(legend.position = \"inside\", legend.position.inside = c(0.85, 0.85))  N_total <- nrow(data_surv_v2) n_event <- sum(data_surv_v2$status_OS == 1) title_text <- glue(\"Overall Survival, (N={N_total}, n event={n_event})\")   km_OS +   add_censor_mark(size = 4, alpha = 0.4) +   labs(     x = \"Time from beginning of treatment to death (months)\",     y = \"Overall Survival\",     title =title_text    )"},{"path":"https://oncostat.github.io/grstat/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Team Oncostat. Copyright holder, funder. Dan Chaltiel. Author, maintainer. Baptiste Archambaud. Contributor. Charlotte Bargain. Contributor. Aldéric Fraslin. Contributor. Nusaïbah Ibrahimi. Contributor. Livia Pierotti. Contributor.","code":""},{"path":"https://oncostat.github.io/grstat/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Chaltiel D (2025). grstat: Clinical Research Tools. R package version 0.1.0.9015, https://oncostat.github.io/grstat/.","code":"@Manual{,   title = {grstat: Clinical Research Tools},   author = {Dan Chaltiel},   year = {2025},   note = {R package version 0.1.0.9015},   url = {https://oncostat.github.io/grstat/}, }"},{"path":"https://oncostat.github.io/grstat/index.html","id":"grstat-","dir":"","previous_headings":"","what":"Clinical Research Tools","title":"Clinical Research Tools","text":"grstat package designed help standardize descriptive clinical research analyses GR.","code":""},{"path":"https://oncostat.github.io/grstat/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"Clinical Research Tools","text":"package CRAN, install GitHub: Note , reproducibility purpose, even better solution use renv.","code":"# Install development version on Github pak::pak(\"Oncostat/grstat@v0.1.0.9015\")"},{"path":"https://oncostat.github.io/grstat/index.html","id":"features","dir":"","previous_headings":"","what":"Features","title":"Clinical Research Tools","text":"See full documentation https://oncostat.github.io/grstat/.","code":""},{"path":"https://oncostat.github.io/grstat/index.html","id":"stable","dir":"","previous_headings":"Features","what":"Stable","title":"Clinical Research Tools","text":"ae_table_grade(), ae_table_soc() ae_plot_grade(), butterfly_plot()","code":""},{"path":"https://oncostat.github.io/grstat/index.html","id":"dev","dir":"","previous_headings":"Features","what":"Dev","title":"Clinical Research Tools","text":"gr_new_project() waterfall_plot()","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade.html","id":null,"dir":"Reference","previous_headings":"","what":"Graphic representation of AEs — ae_plot_grade","title":"Graphic representation of AEs — ae_plot_grade","text":"Produce graphic representation AE, counting AE bars patient, colored grade. Can faceted treatment arm.","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Graphic representation of AEs — ae_plot_grade","text":"","code":"ae_plot_grade(   df_ae,   ...,   df_enrol,   variant = c(\"max\", \"sup\", \"eq\"),   position = c(\"dodge\", \"stack\", \"fill\"),   type = c(\"relative\", \"absolute\"),   arm = NULL,   grade = \"AEGR\",   subjid = \"SUBJID\",   total = FALSE )"},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Graphic representation of AEs — ae_plot_grade","text":"df_ae adverse event dataset, one row per AE, containing subjid, soc, grade. ... unused df_enrol enrollment dataset, one row per patient, containing subjid (arm needed). patients dataset. variant one several c(\"max\", \"sup\", \"eq\"). max computes maximum AE grade per patient, sup computes number patients experienced least one AE grade higher equal X, eq computes number patients experienced least one AE grade equal X. position Position adjustment (cf. ggplot2::geom_col()) type whether present patients proportions (relative) counts (absolute) arm name treatment column df_enrol. Case-insensitive. Can set NULL. grade name AE grade column df_ae. Case-insensitive. subjid name patient ID df_ae df_enrol. Case-insensitive. total whether add total column arm.","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Graphic representation of AEs — ae_plot_grade","text":"ggplot","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Graphic representation of AEs — ae_plot_grade","text":"","code":"tm = grstat_example() attach(tm, warn.conflicts=FALSE) ae_plot_grade(df_ae=ae, df_enrol=enrolres)  ae_plot_grade(df_ae=ae, df_enrol=enrolres, arm=\"ARM\", variant=c(\"sup\", \"max\"))  ae_plot_grade(df_ae=ae, df_enrol=enrolres, arm=\"ARM\", type=\"absolute\")  ae_plot_grade(df_ae=ae, df_enrol=enrolres, arm=\"ARM\", position=\"fill\")  ae_plot_grade(df_ae=ae, df_enrol=enrolres, arm=\"ARM\", position=\"stack\", type=\"absolute\")"},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade_sum.html","id":null,"dir":"Reference","previous_headings":"","what":"Graphic representation of AEs — ae_plot_grade_sum","title":"Graphic representation of AEs — ae_plot_grade_sum","text":"Produce graphic representation AE, counting AE bars patient, colored grade. Can faceted treatment arm.","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade_sum.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Graphic representation of AEs — ae_plot_grade_sum","text":"","code":"ae_plot_grade_sum(   df_ae,   ...,   df_enrol,   low = \"#ffc425\",   high = \"#d11141\",   weights = NULL,   arm = NULL,   grade = \"AEGR\",   subjid = \"SUBJID\" )"},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade_sum.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Graphic representation of AEs — ae_plot_grade_sum","text":"df_ae adverse event dataset, one row per AE, containing subjid, soc, grade. ... unused df_enrol enrollment dataset, one row per patient, containing subjid (arm needed). patients dataset. low color Grade 1 AE high color Grade 5 AE weights (optional) length 5 numeric vector, giving weights grade arm name treatment column df_enrol. Case-insensitive. Can set NULL. grade name AE grade column df_ae. Case-insensitive. subjid name patient ID df_ae df_enrol. Case-insensitive.","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade_sum.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Graphic representation of AEs — ae_plot_grade_sum","text":"ggplot","code":""},{"path":[]},{"path":"https://oncostat.github.io/grstat/reference/ae_plot_grade_sum.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Graphic representation of AEs — ae_plot_grade_sum","text":"","code":"tm = grstat_example() attach(tm, warn.conflicts=FALSE) ae_plot_grade_sum(df_ae=ae, df_enrol=enrolres)  ae_plot_grade_sum(df_ae=ae, df_enrol=enrolres, arm=\"ARM\")  ae_plot_grade_sum(df_ae=ae, df_enrol=enrolres, arm=\"ARM\", weights=c(1,1,3,6,10))"},{"path":"https://oncostat.github.io/grstat/reference/ae_table_grade.html","id":null,"dir":"Reference","previous_headings":"","what":"Summary tables for AE — ae_table_grade","title":"Summary tables for AE — ae_table_grade","text":"function ae_table_grade() creates summary table maximum AE grades patient according CTCAE grade. resulting dataframe can piped as_flextable() get nicely formatted flextable.","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_table_grade.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Summary tables for AE — ae_table_grade","text":"","code":"ae_table_grade(   df_ae,   ...,   df_enrol,   variant = c(\"max\", \"sup\", \"eq\"),   arm = NULL,   grade = \"AEGR\",   subjid = \"SUBJID\",   ae_label = \"AE\",   percent = TRUE,   digits = 2,   total = TRUE )"},{"path":"https://oncostat.github.io/grstat/reference/ae_table_grade.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Summary tables for AE — ae_table_grade","text":"df_ae adverse event dataset, one row per AE, containing subjid, soc, grade. ... unused df_enrol enrollment dataset, one row per patient, containing subjid (arm needed). patients dataset. variant one several c(\"max\", \"sup\", \"eq\"). max computes maximum AE grade per patient, sup computes number patients experienced least one AE grade higher equal X, eq computes number patients experienced least one AE grade equal X. arm name treatment column df_enrol. Case-insensitive. Can set NULL. grade name AE grade column df_ae. Case-insensitive. subjid name patient ID df_ae df_enrol. Case-insensitive. ae_label label adverse events, usually \"AE\" \"SAE\". percent whether show percentages counts. Defaults TRUE. Can also \"\" show counts. digits significant digits percentages. total whether add total column arm.","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_table_grade.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Summary tables for AE — ae_table_grade","text":"crosstable","code":""},{"path":[]},{"path":"https://oncostat.github.io/grstat/reference/ae_table_grade.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Summary tables for AE — ae_table_grade","text":"label variable Treatment arm patients (N=200) Patient maximum AE grade declared AE 8 (4%) Grade 1 38 (19%) Grade 2 62 (31%) Grade 3 54 (27%) Grade 4 34 (17%) Grade 5 4 (2%) Patient least one AE grade declared AE 8 (4%) Grade ≥ 1 192 (96%) Grade ≥ 2 154 (77%) Grade ≥ 3 92 (46%) Grade ≥ 4 38 (19%) Grade = 5 4 (2%) Patient least one AE grade declared AE 8 (4%) Grade 1 164 (82%) Grade 2 110 (55%) Grade 3 62 (31%) Grade 4 36 (18%) Grade 5 4 (2%) label variable Treatment arm Total Control (N=100) Treatment (N=100) Patient maximum AE grade declared AE 3 (3%) 5 (5%) 8 (4%) Grade 1 23 (23%) 15 (15%) 38 (19%) Grade 2 32 (32%) 30 (30%) 62 (31%) Grade 3 27 (27%) 27 (27%) 54 (27%) Grade 4 13 (13%) 21 (21%) 34 (17%) Grade 5 2 (2%) 2 (2%) 4 (2%) Patient least one AE grade declared AE 3 (3%) 5 (5%) 8 (4%) Grade ≥ 1 97 (97%) 95 (95%) 192 (96%) Grade ≥ 2 74 (74%) 80 (80%) 154 (77%) Grade ≥ 3 42 (42%) 50 (50%) 92 (46%) Grade ≥ 4 15 (15%) 23 (23%) 38 (19%) Grade = 5 2 (2%) 2 (2%) 4 (2%) Patient least one AE grade declared AE 3 (3%) 5 (5%) 8 (4%) Grade 1 85 (85%) 79 (79%) 164 (82%) Grade 2 59 (59%) 51 (51%) 110 (55%) Grade 3 30 (30%) 32 (32%) 62 (31%) Grade 4 14 (14%) 22 (22%) 36 (18%) Grade 5 2 (2%) 2 (2%) 4 (2%) label variable Treatment arm Total Control (N=100) Treatment (N=100) Patient maximum SAE grade declared SAE 73 (73%) 71 (71%) 144 (72%) Grade 1 9 (9%) 8 (8%) 17 (8%) Grade 2 8 (8%) 8 (8%) 16 (8%) Grade 3 5 (5%) 6 (6%) 11 (6%) Grade 4 5 (5%) 6 (6%) 11 (6%) Grade 5 0 (0%) 1 (1%) 1 (0%) Patient least one SAE grade declared SAE 73 (73%) 71 (71%) 144 (72%) Grade ≥ 1 27 (27%) 29 (29%) 56 (28%) Grade ≥ 2 18 (18%) 21 (21%) 39 (20%) Grade ≥ 3 10 (10%) 13 (13%) 23 (12%) Grade ≥ 4 5 (5%) 7 (7%) 12 (6%) Grade = 5 0 (0%) 1 (1%) 1 (0%) Patient least one SAE grade declared SAE 73 (73%) 71 (71%) 144 (72%) Grade 1 10 (10%) 8 (8%) 18 (9%) Grade 2 11 (11%) 8 (8%) 19 (10%) Grade 3 5 (5%) 8 (8%) 13 (6%) Grade 4 5 (5%) 6 (6%) 11 (6%) Grade 5 0 (0%) 1 (1%) 1 (0%) label variable Treatment arm Total Control (N=100) Treatment (N=0) Patient maximum AE grade declared AE 3 (3%) 0 (NA) 3 (3%) Grade 1 23 (23%) 0 (NA) 23 (23%) Grade 2 32 (32%) 0 (NA) 32 (32%) Grade 3 27 (27%) 0 (NA) 27 (27%) Grade 4 13 (13%) 0 (NA) 13 (13%) Grade 5 2 (2%) 0 (NA) 2 (2%) Patient least one AE grade declared AE 3 (3%) 0 (NA) 3 (3%) Grade ≥ 1 97 (97%) 0 (NA) 97 (97%) Grade ≥ 2 74 (74%) 0 (NA) 74 (74%) Grade ≥ 3 42 (42%) 0 (NA) 42 (42%) Grade ≥ 4 15 (15%) 0 (NA) 15 (15%) Grade = 5 2 (2%) 0 (NA) 2 (2%) Patient least one AE grade declared AE 3 (3%) 0 (NA) 3 (3%) Grade 1 85 (85%) 0 (NA) 85 (85%) Grade 2 59 (59%) 0 (NA) 59 (59%) Grade 3 30 (30%) 0 (NA) 30 (30%) Grade 4 14 (14%) 0 (NA) 14 (14%) Grade 5 2 (2%) 0 (NA) 2 (2%) label variable Treatment arm Total Control (N=100) Treatment (N=100) Patient maximum AE grade declared AE 3 (3%) 5 (5%) 8 (4%) Grade 3 27 (27%) 27 (27%) 54 (27%) Grade 4 13 (13%) 21 (21%) 34 (17%) Grade 5 2 (2%) 2 (2%) 4 (2%) Patient least one AE grade declared AE 3 (3%) 5 (5%) 8 (4%) Grade ≥ 1 97 (97%) 95 (95%) 192 (96%) Grade ≥ 2 74 (74%) 80 (80%) 154 (77%) Grade ≥ 3 42 (42%) 50 (50%) 92 (46%) Grade ≥ 4 15 (15%) 23 (23%) 38 (19%) Grade = 5 2 (2%) 2 (2%) 4 (2%) Patient least one AE grade declared AE 3 (3%) 5 (5%) 8 (4%) Grade 3 30 (30%) 32 (32%) 62 (31%) Grade 4 14 (14%) 22 (22%) 36 (18%) Grade 5 2 (2%) 2 (2%) 4 (2%)","code":"tm = grstat_example() attach(tm, warn.conflicts=FALSE)  ae_table_grade(df_ae=ae, df_enrol=enrolres, arm=NULL) %>%   as_flextable(header_show_n=TRUE) .cl-f82b8202{table-layout:auto;}.cl-f8250418{font-family:'DejaVu Sans';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-f825042c{font-family:'DejaVu Sans';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-f827b14a{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-f827b154{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-f827ced2{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f827cedc{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f827cedd{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f827cee6{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f827cee7{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f827cef0{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f827cef1{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f827cef2{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f827cefa{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}labelvariableTreatment armAll patients (N=200)Patient maximum AE gradeNo declared AE8 (4%)Grade 138 (19%)Grade 262 (31%)Grade 354 (27%)Grade 434 (17%)Grade 54 (2%)Patient had at least one AE of gradeNo declared AE8 (4%)Grade ≥ 1192 (96%)Grade ≥ 2154 (77%)Grade ≥ 392 (46%)Grade ≥ 438 (19%)Grade = 54 (2%)Patient had at least one AE of grade No declared AE8 (4%)Grade 1164 (82%)Grade 2110 (55%)Grade 362 (31%)Grade 436 (18%)Grade 54 (2%) ae_table_grade(df_ae=ae, df_enrol=enrolres, arm=\"arm\") %>%   as_flextable(header_show_n=TRUE) .cl-f907c636{table-layout:auto;}.cl-f901459a{font-family:'DejaVu Sans';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-f90145ae{font-family:'DejaVu Sans';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-f903f380{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-f903f394{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-f9040f96{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9040fa0{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9040fb4{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9040fb5{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9040fb6{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9040fbe{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9040fc8{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9040fd2{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9040fd3{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}labelvariableTreatment armTotalControl (N=100)Treatment (N=100)Patient maximum AE gradeNo declared AE3 (3%)5 (5%)8 (4%)Grade 123 (23%)15 (15%)38 (19%)Grade 232 (32%)30 (30%)62 (31%)Grade 327 (27%)27 (27%)54 (27%)Grade 413 (13%)21 (21%)34 (17%)Grade 52 (2%)2 (2%)4 (2%)Patient had at least one AE of gradeNo declared AE3 (3%)5 (5%)8 (4%)Grade ≥ 197 (97%)95 (95%)192 (96%)Grade ≥ 274 (74%)80 (80%)154 (77%)Grade ≥ 342 (42%)50 (50%)92 (46%)Grade ≥ 415 (15%)23 (23%)38 (19%)Grade = 52 (2%)2 (2%)4 (2%)Patient had at least one AE of grade No declared AE3 (3%)5 (5%)8 (4%)Grade 185 (85%)79 (79%)164 (82%)Grade 259 (59%)51 (51%)110 (55%)Grade 330 (30%)32 (32%)62 (31%)Grade 414 (14%)22 (22%)36 (18%)Grade 52 (2%)2 (2%)4 (2%) #To get SAE only, filter df_ae first ae %>%   dplyr::filter(sae==\"Yes\") %>%   ae_table_grade(df_enrol=enrolres, arm=\"arm\", ae_label=\"SAE\") %>%   as_flextable(header_show_n=TRUE) .cl-f9dea520{table-layout:auto;}.cl-f9d7d13c{font-family:'DejaVu Sans';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-f9d7d146{font-family:'DejaVu Sans';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-f9da9a70{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-f9da9a84{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-f9dab5c8{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9dab5d2{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9dab5d3{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9dab5d4{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9dab5dc{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9dab5dd{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9dab5de{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9dab5e6{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-f9dab5f0{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}labelvariableTreatment armTotalControl (N=100)Treatment (N=100)Patient maximum SAE gradeNo declared SAE73 (73%)71 (71%)144 (72%)Grade 19 (9%)8 (8%)17 (8%)Grade 28 (8%)8 (8%)16 (8%)Grade 35 (5%)6 (6%)11 (6%)Grade 45 (5%)6 (6%)11 (6%)Grade 50 (0%)1 (1%)1 (0%)Patient had at least one SAE of gradeNo declared SAE73 (73%)71 (71%)144 (72%)Grade ≥ 127 (27%)29 (29%)56 (28%)Grade ≥ 218 (18%)21 (21%)39 (20%)Grade ≥ 310 (10%)13 (13%)23 (12%)Grade ≥ 45 (5%)7 (7%)12 (6%)Grade = 50 (0%)1 (1%)1 (0%)Patient had at least one SAE of grade No declared SAE73 (73%)71 (71%)144 (72%)Grade 110 (10%)8 (8%)18 (9%)Grade 211 (11%)8 (8%)19 (10%)Grade 35 (5%)8 (8%)13 (6%)Grade 45 (5%)6 (6%)11 (6%)Grade 50 (0%)1 (1%)1 (0%) #To describe a sub-population, filter df_enrol first enrolres2 = enrolres %>%   dplyr::filter(arm==\"Control\") ae %>%   ae_table_grade(df_enrol=enrolres2, arm=\"arm\") %>%   as_flextable(header_show_n=TRUE) .cl-faa26f5a{table-layout:auto;}.cl-fa9bad78{font-family:'DejaVu Sans';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fa9bad82{font-family:'DejaVu Sans';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fa9e8cdc{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fa9e8ce6{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fa9eaa82{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fa9eaa8c{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fa9eaa8d{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fa9eaa96{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fa9eaaa0{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fa9eaaa1{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fa9eaaaa{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fa9eaaab{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fa9eaab4{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}labelvariableTreatment armTotalControl (N=100)Treatment (N=0)Patient maximum AE gradeNo declared AE3 (3%)0 (NA)3 (3%)Grade 123 (23%)0 (NA)23 (23%)Grade 232 (32%)0 (NA)32 (32%)Grade 327 (27%)0 (NA)27 (27%)Grade 413 (13%)0 (NA)13 (13%)Grade 52 (2%)0 (NA)2 (2%)Patient had at least one AE of gradeNo declared AE3 (3%)0 (NA)3 (3%)Grade ≥ 197 (97%)0 (NA)97 (97%)Grade ≥ 274 (74%)0 (NA)74 (74%)Grade ≥ 342 (42%)0 (NA)42 (42%)Grade ≥ 415 (15%)0 (NA)15 (15%)Grade = 52 (2%)0 (NA)2 (2%)Patient had at least one AE of grade No declared AE3 (3%)0 (NA)3 (3%)Grade 185 (85%)0 (NA)85 (85%)Grade 259 (59%)0 (NA)59 (59%)Grade 330 (30%)0 (NA)30 (30%)Grade 414 (14%)0 (NA)14 (14%)Grade 52 (2%)0 (NA)2 (2%) #You can also filter the AE table ae %>%   ae_table_grade(df_enrol=enrolres, arm=\"arm\") %>%   dplyr::filter(!variable %in% c(\"Grade 1\", \"Grade 2\")) %>%   as_flextable(header_show_n=TRUE) .cl-fb7d8162{table-layout:auto;}.cl-fb7628d6{font-family:'DejaVu Sans';font-size:11pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fb7628e0{font-family:'DejaVu Sans';font-size:11pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fb78b6fa{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fb78b704{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fb78d20c{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fb78d216{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1.5pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fb78d217{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fb78d218{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fb78d220{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fb78d221{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fb78d222{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fb78d22a{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fb78d22b{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}labelvariableTreatment armTotalControl (N=100)Treatment (N=100)Patient maximum AE gradeNo declared AE3 (3%)5 (5%)8 (4%)Grade 327 (27%)27 (27%)54 (27%)Grade 413 (13%)21 (21%)34 (17%)Grade 52 (2%)2 (2%)4 (2%)Patient had at least one AE of gradeNo declared AE3 (3%)5 (5%)8 (4%)Grade ≥ 197 (97%)95 (95%)192 (96%)Grade ≥ 274 (74%)80 (80%)154 (77%)Grade ≥ 342 (42%)50 (50%)92 (46%)Grade ≥ 415 (15%)23 (23%)38 (19%)Grade = 52 (2%)2 (2%)4 (2%)Patient had at least one AE of grade No declared AE3 (3%)5 (5%)8 (4%)Grade 330 (30%)32 (32%)62 (31%)Grade 414 (14%)22 (22%)36 (18%)Grade 52 (2%)2 (2%)4 (2%)"},{"path":"https://oncostat.github.io/grstat/reference/ae_table_soc.html","id":null,"dir":"Reference","previous_headings":"","what":"Summary tables for AE by SOC — ae_table_soc","title":"Summary tables for AE by SOC — ae_table_soc","text":"function ae_table_soc() creates summary table AE grades patient according term SOC CTCAE. resulting dataframe can piped as_flextable() get nicely formatted flextable.","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_table_soc.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Summary tables for AE by SOC — ae_table_soc","text":"","code":"ae_table_soc(   df_ae,   ...,   df_enrol,   variant = c(\"max\", \"sup\", \"eq\"),   arm = NULL,   term = NULL,   sort_by_count = TRUE,   total = TRUE,   showNA = TRUE,   digits = 0,   warn_miss = FALSE,   grade = \"AEGR\",   soc = \"AESOC\",   subjid = \"SUBJID\" )  # S3 method for class 'ae_table_soc' as_flextable(   x,   ...,   arm_colors = c(\"#f2dcdb\", \"#dbe5f1\", \"#ebf1dd\", \"#e5e0ec\"),   padding_v = NULL )"},{"path":"https://oncostat.github.io/grstat/reference/ae_table_soc.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Summary tables for AE by SOC — ae_table_soc","text":"df_ae adverse event dataset, one row per AE, containing subjid, soc, grade. ... unused df_enrol enrollment dataset, one row per patient, containing subjid (arm needed). patients dataset. variant one several c(\"max\", \"sup\", \"eq\"). max computes maximum AE grade per patient, sup computes number patients experienced least one AE grade higher equal X, eq computes number patients experienced least one AE grade equal X. arm name treatment column df_enrol. Case-insensitive. Can set NULL. term name CTCAE term column df_ae. Case-insensitive. Can set NULL. sort_by_count table sorted number AE SOC alphabetically. total whether add total column arm. showNA whether display missing grades. digits significant digits percentages. warn_miss whether warn missing values. grade name AE grade column df_ae. Case-insensitive. soc name SOC column df_ae. Case-insensitive. Grade considered 0 missing (e.g. patient absent df_ae). subjid name patient ID df_ae df_enrol. Case-insensitive. x dataframe, resulting ae_table_soc() arm_colors colors arm groups padding_v numeric lenght 2, giving vertical padding body (1) header (2)","code":""},{"path":"https://oncostat.github.io/grstat/reference/ae_table_soc.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Summary tables for AE by SOC — ae_table_soc","text":"dataframe (ae_table_soc()) flextable (as_flextable()). formatted flextable","code":""},{"path":[]},{"path":"https://oncostat.github.io/grstat/reference/ae_table_soc.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Summary tables for AE by SOC — ae_table_soc","text":"patients (N=200) CTCAE SOC G1 G2 G3 G4 G5 NA Eye disorders 21 (10%) 16 (8%) 9 (4%) 3 (2%)   Social circumstances 27 (14%) 12 (6%) 6 (3%) 4 (2%)   Congenital, familial genetic disorders 23 (12%) 10 (5%) 4 (2%) 5 (2%)   Injury, poisoning procedural complications 17 (8%) 13 (6%) 3 (2%) 2 (1%)   Immune system disorders 15 (8%) 9 (4%) 7 (4%) 3 (2%)   Pregnancy, puerperium perinatal conditions 14 (7%) 12 (6%) 4 (2%) 3 (2%)   Neoplasms benign, malignant, unspecified 12 (6%) 12 (6%) 4 (2%) 2 (1%)   Hepatobiliary disorders 17 (8%) 8 (4%) 1 (0%) 2 (1%)   Surgical medical procedures 13 (6%) 10 (5%) 4 (2%) 1 (0%)   Cardiac disorders 11 (6%) 4 (2%) 7 (4%) 4 (2%)   Respiratory, thoracic mediastinal disorders 11 (6%) 6 (3%) 5 (2%) 1 (0%) 1 (0%)  Ear labyrinth disorders 7 (4%) 7 (4%) 4 (2%)    Endocrine disorders 11 (6%) 2 (1%) 2 (1%) 1 (0%)   Psychiatric disorders 10 (5%) 2 (1%) 3 (2%) 1 (0%)   Vascular disorders 10 (5%) 3 (2%) 1 (0%) 2 (1%)   Infections infestations 10 (5%) 3 (2%) 1 (0%)  1 (0%)  Musculoskeletal connective tissue disorders 5 (2%) 3 (2%) 4 (2%) 1 (0%) 2 (1%)  Nervous system disorders 5 (2%) 6 (3%)  1 (0%)   Investigations 7 (4%) 1 (0%) 3 (2%)    Blood lymphatic system disorders 3 (2%) 3 (2%) 3 (2%) 1 (0%)   Metabolism nutrition disorders 8 (4%) 2 (1%)     Skin subcutaneous tissue disorders 6 (3%) 3 (2%)  1 (0%)   General disorders administration site conditions 2 (1%) 5 (2%) 2 (1%)    Gastrointestinal disorders 5 (2%) 1 (0%)  1 (0%)   Renal urinary disorders 5 (2%)  1 (0%) 1 (0%)   Reproductive system breast disorders 3 (2%) 2 (1%) 2 (1%)    Declared AE      8 (4%)  patients (N=200) CTCAE SOC G1 G2 G3 G4 G5 NA Tot Blood lymphatic system disorders 3 (2%) 3 (2%) 3 (2%) 1 (0%)   10 (5%) Cardiac disorders 11 (6%) 4 (2%) 7 (4%) 4 (2%)   26 (13%) Congenital, familial genetic disorders 23 (12%) 10 (5%) 4 (2%) 5 (2%)   42 (21%) Ear labyrinth disorders 7 (4%) 7 (4%) 4 (2%)    18 (9%) Endocrine disorders 11 (6%) 2 (1%) 2 (1%) 1 (0%)   16 (8%) Eye disorders 21 (10%) 16 (8%) 9 (4%) 3 (2%)   49 (24%) Gastrointestinal disorders 5 (2%) 1 (0%)  1 (0%)   7 (4%) General disorders administration site conditions 2 (1%) 5 (2%) 2 (1%)    9 (4%) Hepatobiliary disorders 17 (8%) 8 (4%) 1 (0%) 2 (1%)   28 (14%) Immune system disorders 15 (8%) 9 (4%) 7 (4%) 3 (2%)   34 (17%) Infections infestations 10 (5%) 3 (2%) 1 (0%)  1 (0%)  15 (8%) Injury, poisoning procedural complications 17 (8%) 13 (6%) 3 (2%) 2 (1%)   35 (18%) Investigations 7 (4%) 1 (0%) 3 (2%)    11 (6%) Metabolism nutrition disorders 8 (4%) 2 (1%)     10 (5%) Musculoskeletal connective tissue disorders 5 (2%) 3 (2%) 4 (2%) 1 (0%) 2 (1%)  15 (8%) Neoplasms benign, malignant, unspecified 12 (6%) 12 (6%) 4 (2%) 2 (1%)   30 (15%) Nervous system disorders 5 (2%) 6 (3%)  1 (0%)   12 (6%) Pregnancy, puerperium perinatal conditions 14 (7%) 12 (6%) 4 (2%) 3 (2%)   33 (16%) Psychiatric disorders 10 (5%) 2 (1%) 3 (2%) 1 (0%)   16 (8%) Renal urinary disorders 5 (2%)  1 (0%) 1 (0%)   7 (4%) Reproductive system breast disorders 3 (2%) 2 (1%) 2 (1%)    7 (4%) Respiratory, thoracic mediastinal disorders 11 (6%) 6 (3%) 5 (2%) 1 (0%) 1 (0%)  24 (12%) Skin subcutaneous tissue disorders 6 (3%) 3 (2%)  1 (0%)   10 (5%) Social circumstances 27 (14%) 12 (6%) 6 (3%) 4 (2%)   49 (24%) Surgical medical procedures 13 (6%) 10 (5%) 4 (2%) 1 (0%)   28 (14%) Vascular disorders 10 (5%) 3 (2%) 1 (0%) 2 (1%)   16 (8%) Declared AE      8 (4%) 8 (4%)  patients (N=200) CTCAE SOC CTCAE v4.0 Term G1 G2 G3 G4 G5 NA Tot Social circumstances Cultural issues 11 (6%) 3 (2%) 3 (2%) 2 (1%)   19 (10%) Economic conditions affecting care 2 (1%) 4 (2%)  1 (0%)   7 (4%) Family support issues 14 (7%) 4 (2%) 2 (1%)    20 (10%) Social environmental issues 7 (4%) 2 (1%) 2 (1%) 1 (0%)   12 (6%) Eye disorders Corneal disorders 8 (4%) 3 (2%) 1 (0%)    12 (6%) Eyelid disorders 5 (2%) 3 (2%) 2 (1%)    10 (5%) Retinal disorders 6 (3%) 6 (3%) 4 (2%) 2 (1%)   18 (9%) Vision disorders 6 (3%) 4 (2%) 2 (1%) 1 (0%)   13 (6%) Congenital, familial genetic disorders Chromosomal abnormalities 5 (2%) 2 (1%) 2 (1%) 3 (2%)   12 (6%) Congenital nervous system disorders 10 (5%) 4 (2%)     14 (7%) Familial hematologic disorders 5 (2%) 2 (1%)  1 (0%)   8 (4%) Hereditary connective tissue disorders 8 (4%) 2 (1%) 2 (1%) 1 (0%)   13 (6%) Injury, poisoning procedural complications Poisonings 4 (2%) 4 (2%) 1 (0%)    9 (4%) Procedural complications 12 (6%) 1 (0%) 2 (1%) 1 (0%)   16 (8%) Radiation-related toxicities 2 (1%) 4 (2%)  1 (0%)   7 (4%) Traumatic injuries 3 (2%) 4 (2%)     7 (4%) Immune system disorders Autoimmune disorders 3 (2%) 1 (0%) 1 (0%) 1 (0%)   6 (3%) Hypersensitivity conditions 7 (4%) 4 (2%) 2 (1%) 1 (0%)   14 (7%) Immunodeficiency 2 (1%) 2 (1%) 2 (1%)    6 (3%) Inflammatory responses 4 (2%) 4 (2%) 2 (1%) 1 (0%)   11 (6%) Pregnancy, puerperium perinatal conditions Breastfeeding issues 3 (2%) 2 (1%)     5 (2%) Fetal complications 2 (1%) 7 (4%) 1 (0%) 2 (1%)   12 (6%) Labor delivery complications 6 (3%) 1 (0%) 2 (1%) 1 (0%)   10 (5%) Pregnancy complications 4 (2%) 2 (1%) 1 (0%)    7 (4%) Neoplasms benign, malignant, unspecified Benign neoplasms 4 (2%) 7 (4%) 1 (0%) 1 (0%)   13 (6%) Malignant neoplasms 2 (1%) 1 (0%)     3 (2%) Neoplasms unspecified 1 (0%) 2 (1%) 2 (1%)    5 (2%) Tumor progression 5 (2%) 3 (2%) 1 (0%) 1 (0%)   10 (5%) Hepatobiliary disorders Bile duct disorders 4 (2%) 4 (2%)  1 (0%)   9 (4%) Gallbladder disorders 4 (2%) 1 (0%)  1 (0%)   6 (3%) Hepatic failure 5 (2%) 2 (1%)     7 (4%) Liver disorders 6 (3%) 1 (0%) 1 (0%)    8 (4%) Surgical medical procedures Device implantation procedures 5 (2%) 1 (0%) 1 (0%)    7 (4%) Diagnostic procedures 3 (2%) 3 (2%) 1 (0%)    7 (4%) Surgical complications 3 (2%) 3 (2%) 2 (1%)    8 (4%) Therapeutic procedures 3 (2%) 3 (2%) 1 (0%) 1 (0%)   8 (4%) Cardiac disorders Cardiac arrhythmias 5 (2%) 2 (1%) 1 (0%) 1 (0%)   9 (4%) Cardiac valve disorders 3 (2%) 1 (0%) 5 (2%) 2 (1%)   11 (6%) Coronary artery disorders 3 (2%)   1 (0%)   4 (2%) Heart failures 2 (1%) 1 (0%) 1 (0%)    4 (2%) Respiratory, thoracic mediastinal disorders Lung function disorders 2 (1%) 2 (1%) 3 (2%)    7 (4%) Pleural disorders 3 (2%)  1 (0%)  1 (0%)  5 (2%) Pulmonary vascular disorders 5 (2%) 1 (0%)  1 (0%)   7 (4%) Respiratory infections 2 (1%) 3 (2%) 2 (1%)    7 (4%) Ear labyrinth disorders Hearing disorders 2 (1%) 1 (0%) 1 (0%)    4 (2%) Labyrinth disorders 1 (0%) 2 (1%) 1 (0%)    4 (2%) Tinnitus 2 (1%) 2 (1%) 2 (1%)    6 (3%) Vertigo balance disorders 2 (1%) 2 (1%)     4 (2%) Endocrine disorders Adrenal gland disorders 3 (2%)      3 (2%) Parathyroid gland disorders 3 (2%)      3 (2%) Pituitary gland disorders 4 (2%) 1 (0%)     5 (2%) Thyroid gland disorders 2 (1%) 1 (0%) 2 (1%) 1 (0%)   6 (3%) Psychiatric disorders Anxiety disorders 2 (1%) 2 (1%) 1 (0%)    5 (2%) Mood disorders 2 (1%)  2 (1%)    4 (2%) Sleep disorders 4 (2%)   1 (0%)   5 (2%) Substance-related disorders 3 (2%)      3 (2%) Infections infestations Bacterial infectious disorders 2 (1%)      2 (1%) Fungal infectious disorders 1 (0%)    1 (0%)  2 (1%) Parasitic infectious disorders 5 (2%) 2 (1%) 1 (0%)    8 (4%) Viral infectious disorders 3 (2%) 1 (0%)     4 (2%) Vascular disorders Hypertension-related conditions  2 (1%) 1 (0%)    3 (2%) Hypotension-related conditions 3 (2%)      3 (2%) Vascular hemorrhagic disorders 5 (2%)   1 (0%)   6 (3%) Venous thromboembolic events 2 (1%) 1 (0%)  1 (0%)   4 (2%) Musculoskeletal connective tissue disorders Arthritis joint disorders  2 (1%)   1 (0%)  3 (2%) Bone disorders  1 (0%) 2 (1%)  1 (0%)  4 (2%) Connective tissue disorders 3 (2%)  1 (0%) 1 (0%)   5 (2%) Muscle disorders 2 (1%)  1 (0%)    3 (2%) Nervous system disorders Headache disorders 3 (2%) 1 (0%)  1 (0%)   5 (2%) Neurological disorders central nervous system 1 (0%) 2 (1%)     3 (2%) Peripheral neuropathies  2 (1%)     2 (1%) Seizure disorders 2 (1%) 1 (0%)     3 (2%) Investigations Blood analyses 2 (1%)  1 (0%)    3 (2%) Cardiovascular assessments 2 (1%)  1 (0%)    3 (2%) Imaging studies  1 (0%) 1 (0%)    2 (1%) Liver function analyses 3 (2%)      3 (2%) Metabolism nutrition disorders Fluid electrolyte disorders 2 (1%)      2 (1%) Lipid metabolism disorders 3 (2%)      3 (2%) Nutritional disorders 2 (1%) 1 (0%)     3 (2%) Vitamin deficiencies 2 (1%) 1 (0%)     3 (2%) Blood lymphatic system disorders Bone marrow disorders    1 (0%)   1 (0%) Coagulation bleeding analyses   1 (0%)    1 (0%) Hematologic neoplasms   1 (0%)    1 (0%) Red blood cell disorders 3 (2%) 3 (2%) 1 (0%)    7 (4%) Skin subcutaneous tissue disorders Dermatitis 2 (1%) 1 (0%)     3 (2%) Skin subcutaneous tissue injuries 1 (0%) 1 (0%)     2 (1%) Skin infections 2 (1%)      2 (1%) Skin pigmentation disorders 1 (0%) 1 (0%)  1 (0%)   3 (2%) General disorders administration site conditions General physical health deterioration  3 (2%)     3 (2%) Injection site reactions 1 (0%) 1 (0%) 2 (1%)    4 (2%) Pain discomfort 1 (0%) 1 (0%)     2 (1%) Gastrointestinal disorders Esophageal disorders 1 (0%)   1 (0%)   2 (1%) Gastric disorders 2 (1%)      2 (1%) Intestinal disorders 2 (1%) 1 (0%)     3 (2%) Renal urinary disorders Bladder disorders    1 (0%)   1 (0%) Kidney disorders 2 (1%)      2 (1%) Urethral disorders 1 (0%)  1 (0%)    2 (1%) Urinary tract disorders 2 (1%)      2 (1%) Reproductive system breast disorders Breast disorders   1 (0%)    1 (0%) Female reproductive disorders 1 (0%)  1 (0%)    2 (1%) Male reproductive disorders 1 (0%) 2 (1%)     3 (2%) Menstrual disorders 1 (0%)      1 (0%) Declared AE       8 (4%) 8 (4%)","code":"tm = grstat_example() attach(tm, warn.conflicts=FALSE)  ae_table_soc(df_ae=ae, df_enrol=enrolres) #> # A tibble: 27 × 8 #>    soc           all_patients_G1 all_patients_G2 all_patients_G3 all_patients_G4 #>    <fct>         <glue>          <glue>          <glue>          <glue>          #>  1 Eye disorders 21 (10%)        16 (8%)         9 (4%)          3 (2%)          #>  2 Social circu… 27 (14%)        12 (6%)         6 (3%)          4 (2%)          #>  3 Congenital, … 23 (12%)        10 (5%)         4 (2%)          5 (2%)          #>  4 Injury, pois… 17 (8%)         13 (6%)         3 (2%)          2 (1%)          #>  5 Immune syste… 15 (8%)         9 (4%)          7 (4%)          3 (2%)          #>  6 Pregnancy, p… 14 (7%)         12 (6%)         4 (2%)          3 (2%)          #>  7 Neoplasms be… 12 (6%)         12 (6%)         4 (2%)          2 (1%)          #>  8 Hepatobiliar… 17 (8%)         8 (4%)          1 (0%)          2 (1%)          #>  9 Surgical and… 13 (6%)         10 (5%)         4 (2%)          1 (0%)          #> 10 Cardiac diso… 11 (6%)         4 (2%)          7 (4%)          4 (2%)          #> # ℹ 17 more rows #> # ℹ 3 more variables: all_patients_G5 <glue>, all_patients_NA <glue>, #> #   all_patients_Tot <glue> ae_table_soc(df_ae=ae, df_enrol=enrolres, arm=\"arm\") #> # A tibble: 27 × 15 #>    soc         control_G1 control_G2 control_G3 control_G4 control_G5 control_NA #>    <fct>       <glue>     <glue>     <glue>     <glue>     <glue>     <glue>     #>  1 Eye disord… 14 (14%)   11 (11%)   4 (4%)     2 (2%)     NA         NA         #>  2 Social cir… 16 (16%)   8 (8%)     3 (3%)     NA         NA         NA         #>  3 Congenital… 10 (10%)   7 (7%)     2 (2%)     1 (1%)     NA         NA         #>  4 Injury, po… 12 (12%)   8 (8%)     1 (1%)     1 (1%)     NA         NA         #>  5 Immune sys… 8 (8%)     4 (4%)     4 (4%)     2 (2%)     NA         NA         #>  6 Pregnancy,… 7 (7%)     5 (5%)     2 (2%)     2 (2%)     NA         NA         #>  7 Neoplasms … 6 (6%)     7 (7%)     3 (3%)     1 (1%)     NA         NA         #>  8 Hepatobili… 9 (9%)     3 (3%)     NA         2 (2%)     NA         NA         #>  9 Surgical a… 6 (6%)     5 (5%)     2 (2%)     NA         NA         NA         #> 10 Cardiac di… 7 (7%)     3 (3%)     4 (4%)     NA         NA         NA         #> # ℹ 17 more rows #> # ℹ 8 more variables: control_Tot <glue>, treatment_G1 <glue>, #> #   treatment_G2 <glue>, treatment_G3 <glue>, treatment_G4 <glue>, #> #   treatment_G5 <glue>, treatment_NA <glue>, treatment_Tot <glue>  #sub population ae_table_soc(df_ae=ae, df_enrol=head(enrolres, 10), arm=\"arm\") #> # A tibble: 16 × 15 #>    soc         control_G1 control_G2 control_G3 control_G4 control_G5 control_NA #>    <fct>       <glue>     <glue>     <glue>     <glue>     <glue>     <glue>     #>  1 Eye disord… 3 (60%)    NA         1 (20%)    NA         NA         NA         #>  2 Pregnancy,… 3 (60%)    1 (20%)    NA         NA         NA         NA         #>  3 Psychiatri… 1 (20%)    NA         NA         NA         NA         NA         #>  4 Social cir… 1 (20%)    NA         NA         NA         NA         NA         #>  5 Cardiac di… NA         1 (20%)    NA         NA         NA         NA         #>  6 Metabolism… 1 (20%)    NA         NA         NA         NA         NA         #>  7 Neoplasms … NA         NA         2 (40%)    NA         NA         NA         #>  8 Surgical a… NA         NA         NA         NA         NA         NA         #>  9 Congenital… 1 (20%)    NA         NA         NA         NA         NA         #> 10 Ear and la… 1 (20%)    NA         NA         NA         NA         NA         #> 11 Infections… 1 (20%)    NA         NA         NA         NA         NA         #> 12 Injury, po… NA         1 (20%)    NA         NA         NA         NA         #> 13 Investigat… 1 (20%)    NA         NA         NA         NA         NA         #> 14 Musculoske… NA         NA         1 (20%)    NA         NA         NA         #> 15 Respirator… NA         NA         NA         NA         NA         NA         #> 16 Vascular d… 1 (20%)    NA         NA         NA         NA         NA         #> # ℹ 8 more variables: control_Tot <glue>, treatment_G1 <glue>, #> #   treatment_G2 <glue>, treatment_G3 <glue>, treatment_G4 <glue>, #> #   treatment_G5 <glue>, treatment_NA <glue>, treatment_Tot <glue>  #the resulting flextable can be customized using the flextable package library(flextable) ae_table_soc(ae, df_enrol=enrolres, total=FALSE) %>%   as_flextable() %>%   hline(i=~soc==\"\" & soc!=dplyr::lead(soc)) .cl-fce2a500{table-layout:auto;}.cl-fcdb3824{font-family:'DejaVu Sans';font-size:8pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fcdb3838{font-family:'DejaVu Sans';font-size:8pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fcde2b38{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fcde2b42{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fcde2b4c{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fcde2b4d{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fcde2b56{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fcde491a{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fcde4924{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fcde492e{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fcde492f{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fcde4930{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fcde4938{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fcde4939{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fcde4942{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}All patients (N=200)CTCAE SOCG1G2G3G4G5NAEye disorders21 (10%)16 (8%)9 (4%)3 (2%)Social circumstances27 (14%)12 (6%)6 (3%)4 (2%)Congenital, familial and genetic disorders23 (12%)10 (5%)4 (2%)5 (2%)Injury, poisoning and procedural complications17 (8%)13 (6%)3 (2%)2 (1%)Immune system disorders15 (8%)9 (4%)7 (4%)3 (2%)Pregnancy, puerperium and perinatal conditions14 (7%)12 (6%)4 (2%)3 (2%)Neoplasms benign, malignant, and unspecified12 (6%)12 (6%)4 (2%)2 (1%)Hepatobiliary disorders17 (8%)8 (4%)1 (0%)2 (1%)Surgical and medical procedures13 (6%)10 (5%)4 (2%)1 (0%)Cardiac disorders11 (6%)4 (2%)7 (4%)4 (2%)Respiratory, thoracic and mediastinal disorders11 (6%)6 (3%)5 (2%)1 (0%)1 (0%)Ear and labyrinth disorders7 (4%)7 (4%)4 (2%)Endocrine disorders11 (6%)2 (1%)2 (1%)1 (0%)Psychiatric disorders10 (5%)2 (1%)3 (2%)1 (0%)Vascular disorders10 (5%)3 (2%)1 (0%)2 (1%)Infections and infestations10 (5%)3 (2%)1 (0%)1 (0%)Musculoskeletal and connective tissue disorders5 (2%)3 (2%)4 (2%)1 (0%)2 (1%)Nervous system disorders5 (2%)6 (3%)1 (0%)Investigations7 (4%)1 (0%)3 (2%)Blood and lymphatic system disorders3 (2%)3 (2%)3 (2%)1 (0%)Metabolism and nutrition disorders8 (4%)2 (1%)Skin and subcutaneous tissue disorders6 (3%)3 (2%)1 (0%)General disorders and administration site conditions2 (1%)5 (2%)2 (1%)Gastrointestinal disorders5 (2%)1 (0%)1 (0%)Renal and urinary disorders5 (2%)1 (0%)1 (0%)Reproductive system and breast disorders3 (2%)2 (1%)2 (1%)No Declared AE8 (4%)ae_table_soc(ae, df_enrol=enrolres, term=NULL, sort_by_count=FALSE) %>%   as_flextable() %>%   bold(i=~soc==\"Eye disorders\") .cl-fd2d2198{table-layout:auto;}.cl-fd25b4ee{font-family:'DejaVu Sans';font-size:8pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fd25b502{font-family:'DejaVu Sans';font-size:8pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fd2898f8{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fd289902{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fd28990c{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fd28990d{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fd289916{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fd28b680{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fd28b681{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fd28b68a{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fd28b694{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fd28b695{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fd28b696{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fd28b69e{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fd28b6a8{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}All patients (N=200)CTCAE SOCG1G2G3G4G5NATotBlood and lymphatic system disorders3 (2%)3 (2%)3 (2%)1 (0%)10 (5%)Cardiac disorders11 (6%)4 (2%)7 (4%)4 (2%)26 (13%)Congenital, familial and genetic disorders23 (12%)10 (5%)4 (2%)5 (2%)42 (21%)Ear and labyrinth disorders7 (4%)7 (4%)4 (2%)18 (9%)Endocrine disorders11 (6%)2 (1%)2 (1%)1 (0%)16 (8%)Eye disorders21 (10%)16 (8%)9 (4%)3 (2%)49 (24%)Gastrointestinal disorders5 (2%)1 (0%)1 (0%)7 (4%)General disorders and administration site conditions2 (1%)5 (2%)2 (1%)9 (4%)Hepatobiliary disorders17 (8%)8 (4%)1 (0%)2 (1%)28 (14%)Immune system disorders15 (8%)9 (4%)7 (4%)3 (2%)34 (17%)Infections and infestations10 (5%)3 (2%)1 (0%)1 (0%)15 (8%)Injury, poisoning and procedural complications17 (8%)13 (6%)3 (2%)2 (1%)35 (18%)Investigations7 (4%)1 (0%)3 (2%)11 (6%)Metabolism and nutrition disorders8 (4%)2 (1%)10 (5%)Musculoskeletal and connective tissue disorders5 (2%)3 (2%)4 (2%)1 (0%)2 (1%)15 (8%)Neoplasms benign, malignant, and unspecified12 (6%)12 (6%)4 (2%)2 (1%)30 (15%)Nervous system disorders5 (2%)6 (3%)1 (0%)12 (6%)Pregnancy, puerperium and perinatal conditions14 (7%)12 (6%)4 (2%)3 (2%)33 (16%)Psychiatric disorders10 (5%)2 (1%)3 (2%)1 (0%)16 (8%)Renal and urinary disorders5 (2%)1 (0%)1 (0%)7 (4%)Reproductive system and breast disorders3 (2%)2 (1%)2 (1%)7 (4%)Respiratory, thoracic and mediastinal disorders11 (6%)6 (3%)5 (2%)1 (0%)1 (0%)24 (12%)Skin and subcutaneous tissue disorders6 (3%)3 (2%)1 (0%)10 (5%)Social circumstances27 (14%)12 (6%)6 (3%)4 (2%)49 (24%)Surgical and medical procedures13 (6%)10 (5%)4 (2%)1 (0%)28 (14%)Vascular disorders10 (5%)3 (2%)1 (0%)2 (1%)16 (8%)No Declared AE8 (4%)8 (4%)ae_table_soc(ae, df_enrol=enrolres, term=\"aeterm\", arm=NULL) %>%   as_flextable() %>%   highlight(i=~soc==\"Hepatobiliary disorders\", j=\"all_patients_Tot\") .cl-fdbbbd90{table-layout:auto;}.cl-fdad7be0{font-family:'DejaVu Sans';font-size:8pt;font-weight:bold;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fdad7bf4{font-family:'DejaVu Sans';font-size:8pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:transparent;}.cl-fdad7bf5{font-family:'DejaVu Sans';font-size:8pt;font-weight:normal;font-style:normal;text-decoration:none;color:rgba(0, 0, 0, 1.00);background-color:rgba(255, 255, 0, 1.00);}.cl-fdb1b494{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fdb1b49e{margin:0;text-align:center;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fdb1b4a8{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:5pt;padding-top:5pt;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fdb1b4b2{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fdb1b4b3{margin:0;text-align:right;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fdb1b4bc{margin:0;text-align:left;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);padding-bottom:0;padding-top:0;padding-left:5pt;padding-right:5pt;line-height: 1;background-color:transparent;}.cl-fdb1e82e{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e838{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 0 solid rgba(255, 255, 255, 0.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e839{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e842{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 1pt solid rgba(102, 102, 102, 1.00);border-top: 0 solid rgba(255, 255, 255, 0.00);border-left: 0 solid rgba(255, 255, 255, 0.00);border-right: 0 solid rgba(255, 255, 255, 0.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e843{background-color:transparent;vertical-align: top;border-bottom: 1pt solid rgba(190, 190, 190, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e84c{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e84d{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e84e{background-color:transparent;vertical-align: top;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e856{background-color:transparent;vertical-align: middle;border-bottom: 1pt solid rgba(190, 190, 190, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e860{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 1pt solid rgba(190, 190, 190, 1.00);border-top: 0 solid rgba(0, 0, 0, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e861{background-color:transparent;vertical-align: top;border-bottom: 1pt solid rgba(190, 190, 190, 1.00);border-top: 1pt solid rgba(190, 190, 190, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e862{background-color:transparent;vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(190, 190, 190, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e86a{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 0 solid rgba(0, 0, 0, 1.00);border-top: 1pt solid rgba(190, 190, 190, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e86b{background-color:transparent;vertical-align: top;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(190, 190, 190, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e86c{background-color:transparent;vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(190, 190, 190, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}.cl-fdb1e874{background-color:rgba(242, 220, 219, 1.00);vertical-align: middle;border-bottom: 1.5pt solid rgba(102, 102, 102, 1.00);border-top: 1pt solid rgba(190, 190, 190, 1.00);border-left: 0 solid rgba(0, 0, 0, 1.00);border-right: 0 solid rgba(0, 0, 0, 1.00);margin-bottom:0;margin-top:0;margin-left:0;margin-right:0;}All patients (N=200)CTCAE SOCCTCAE v4.0 TermG1G2G3G4G5NATotSocial circumstancesCultural issues11 (6%)3 (2%)3 (2%)2 (1%)19 (10%)Economic conditions affecting care2 (1%)4 (2%)1 (0%)7 (4%)Family support issues14 (7%)4 (2%)2 (1%)20 (10%)Social and environmental issues7 (4%)2 (1%)2 (1%)1 (0%)12 (6%)Eye disordersCorneal disorders8 (4%)3 (2%)1 (0%)12 (6%)Eyelid disorders5 (2%)3 (2%)2 (1%)10 (5%)Retinal disorders6 (3%)6 (3%)4 (2%)2 (1%)18 (9%)Vision disorders6 (3%)4 (2%)2 (1%)1 (0%)13 (6%)Congenital, familial and genetic disordersChromosomal abnormalities5 (2%)2 (1%)2 (1%)3 (2%)12 (6%)Congenital nervous system disorders10 (5%)4 (2%)14 (7%)Familial hematologic disorders5 (2%)2 (1%)1 (0%)8 (4%)Hereditary connective tissue disorders8 (4%)2 (1%)2 (1%)1 (0%)13 (6%)Injury, poisoning and procedural complicationsPoisonings4 (2%)4 (2%)1 (0%)9 (4%)Procedural complications12 (6%)1 (0%)2 (1%)1 (0%)16 (8%)Radiation-related toxicities2 (1%)4 (2%)1 (0%)7 (4%)Traumatic injuries3 (2%)4 (2%)7 (4%)Immune system disordersAutoimmune disorders3 (2%)1 (0%)1 (0%)1 (0%)6 (3%)Hypersensitivity conditions7 (4%)4 (2%)2 (1%)1 (0%)14 (7%)Immunodeficiency2 (1%)2 (1%)2 (1%)6 (3%)Inflammatory responses4 (2%)4 (2%)2 (1%)1 (0%)11 (6%)Pregnancy, puerperium and perinatal conditionsBreastfeeding issues3 (2%)2 (1%)5 (2%)Fetal complications2 (1%)7 (4%)1 (0%)2 (1%)12 (6%)Labor and delivery complications6 (3%)1 (0%)2 (1%)1 (0%)10 (5%)Pregnancy complications4 (2%)2 (1%)1 (0%)7 (4%)Neoplasms benign, malignant, and unspecifiedBenign neoplasms4 (2%)7 (4%)1 (0%)1 (0%)13 (6%)Malignant neoplasms2 (1%)1 (0%)3 (2%)Neoplasms unspecified1 (0%)2 (1%)2 (1%)5 (2%)Tumor progression5 (2%)3 (2%)1 (0%)1 (0%)10 (5%)Hepatobiliary disordersBile duct disorders4 (2%)4 (2%)1 (0%)9 (4%)Gallbladder disorders4 (2%)1 (0%)1 (0%)6 (3%)Hepatic failure5 (2%)2 (1%)7 (4%)Liver disorders6 (3%)1 (0%)1 (0%)8 (4%)Surgical and medical proceduresDevice implantation procedures5 (2%)1 (0%)1 (0%)7 (4%)Diagnostic procedures3 (2%)3 (2%)1 (0%)7 (4%)Surgical complications3 (2%)3 (2%)2 (1%)8 (4%)Therapeutic procedures3 (2%)3 (2%)1 (0%)1 (0%)8 (4%)Cardiac disordersCardiac arrhythmias5 (2%)2 (1%)1 (0%)1 (0%)9 (4%)Cardiac valve disorders3 (2%)1 (0%)5 (2%)2 (1%)11 (6%)Coronary artery disorders3 (2%)1 (0%)4 (2%)Heart failures2 (1%)1 (0%)1 (0%)4 (2%)Respiratory, thoracic and mediastinal disordersLung function disorders2 (1%)2 (1%)3 (2%)7 (4%)Pleural disorders3 (2%)1 (0%)1 (0%)5 (2%)Pulmonary vascular disorders5 (2%)1 (0%)1 (0%)7 (4%)Respiratory infections2 (1%)3 (2%)2 (1%)7 (4%)Ear and labyrinth disordersHearing disorders2 (1%)1 (0%)1 (0%)4 (2%)Labyrinth disorders1 (0%)2 (1%)1 (0%)4 (2%)Tinnitus2 (1%)2 (1%)2 (1%)6 (3%)Vertigo and balance disorders2 (1%)2 (1%)4 (2%)Endocrine disordersAdrenal gland disorders3 (2%)3 (2%)Parathyroid gland disorders3 (2%)3 (2%)Pituitary gland disorders4 (2%)1 (0%)5 (2%)Thyroid gland disorders2 (1%)1 (0%)2 (1%)1 (0%)6 (3%)Psychiatric disordersAnxiety disorders2 (1%)2 (1%)1 (0%)5 (2%)Mood disorders2 (1%)2 (1%)4 (2%)Sleep disorders4 (2%)1 (0%)5 (2%)Substance-related disorders3 (2%)3 (2%)Infections and infestationsBacterial infectious disorders2 (1%)2 (1%)Fungal infectious disorders1 (0%)1 (0%)2 (1%)Parasitic infectious disorders5 (2%)2 (1%)1 (0%)8 (4%)Viral infectious disorders3 (2%)1 (0%)4 (2%)Vascular disordersHypertension-related conditions2 (1%)1 (0%)3 (2%)Hypotension-related conditions3 (2%)3 (2%)Vascular hemorrhagic disorders5 (2%)1 (0%)6 (3%)Venous thromboembolic events2 (1%)1 (0%)1 (0%)4 (2%)Musculoskeletal and connective tissue disordersArthritis and joint disorders2 (1%)1 (0%)3 (2%)Bone disorders1 (0%)2 (1%)1 (0%)4 (2%)Connective tissue disorders3 (2%)1 (0%)1 (0%)5 (2%)Muscle disorders2 (1%)1 (0%)3 (2%)Nervous system disordersHeadache disorders3 (2%)1 (0%)1 (0%)5 (2%)Neurological disorders of the central nervous system1 (0%)2 (1%)3 (2%)Peripheral neuropathies2 (1%)2 (1%)Seizure disorders2 (1%)1 (0%)3 (2%)InvestigationsBlood analyses2 (1%)1 (0%)3 (2%)Cardiovascular assessments2 (1%)1 (0%)3 (2%)Imaging studies1 (0%)1 (0%)2 (1%)Liver function analyses3 (2%)3 (2%)Metabolism and nutrition disordersFluid and electrolyte disorders2 (1%)2 (1%)Lipid metabolism disorders3 (2%)3 (2%)Nutritional disorders2 (1%)1 (0%)3 (2%)Vitamin deficiencies2 (1%)1 (0%)3 (2%)Blood and lymphatic system disordersBone marrow disorders1 (0%)1 (0%)Coagulation and bleeding analyses1 (0%)1 (0%)Hematologic neoplasms1 (0%)1 (0%)Red blood cell disorders3 (2%)3 (2%)1 (0%)7 (4%)Skin and subcutaneous tissue disordersDermatitis2 (1%)1 (0%)3 (2%)Skin and subcutaneous tissue injuries1 (0%)1 (0%)2 (1%)Skin infections2 (1%)2 (1%)Skin pigmentation disorders1 (0%)1 (0%)1 (0%)3 (2%)General disorders and administration site conditionsGeneral physical health deterioration3 (2%)3 (2%)Injection site reactions1 (0%)1 (0%)2 (1%)4 (2%)Pain and discomfort1 (0%)1 (0%)2 (1%)Gastrointestinal disordersEsophageal disorders1 (0%)1 (0%)2 (1%)Gastric disorders2 (1%)2 (1%)Intestinal disorders2 (1%)1 (0%)3 (2%)Renal and urinary disordersBladder disorders1 (0%)1 (0%)Kidney disorders2 (1%)2 (1%)Urethral disorders1 (0%)1 (0%)2 (1%)Urinary tract disorders2 (1%)2 (1%)Reproductive system and breast disordersBreast disorders1 (0%)1 (0%)Female reproductive disorders1 (0%)1 (0%)2 (1%)Male reproductive disorders1 (0%)2 (1%)3 (2%)Menstrual disorders1 (0%)1 (0%)No Declared AE8 (4%)8 (4%)"},{"path":"https://oncostat.github.io/grstat/reference/boin_plot.html","id":null,"dir":"Reference","previous_headings":"","what":"Plot BOIN decision boundaries and patient-level data — boin_plot","title":"Plot BOIN decision boundaries and patient-level data — boin_plot","text":"Generates plot decision boundaries BOIN design, optionally overlaid patient-level data Gantt-style timeline.","code":""},{"path":"https://oncostat.github.io/grstat/reference/boin_plot.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Plot BOIN decision boundaries and patient-level data — boin_plot","text":"","code":"boin_plot(   data_boin,   data_patients = NULL,   ...,   doses,   gantt_include = FALSE,   gantt_labels = NULL )"},{"path":"https://oncostat.github.io/grstat/reference/boin_plot.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Plot BOIN decision boundaries and patient-level data — boin_plot","text":"data_boin boin object BOIN::get.boundary() function data.frame columns n_eval, escalate_if_inf, deescalate_if_sup, eliminate_if_sup. data_patients Optional data frame containing patient-level information, columns subjid, dose (character), dlt (logical). gantt_include==TRUE, must also include DLT evaluation period date_dlt_start date_dlt_end. ... Unused. doses Vector dose labels, matching order dose levels BOIN design. gantt_include Logical, whether include Gantt chart follow-. gantt_labels Optional vector labels names dates values, display Gantt chart.","code":""},{"path":"https://oncostat.github.io/grstat/reference/boin_plot.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Plot BOIN decision boundaries and patient-level data — boin_plot","text":"ggplot2 object showing BOIN decision rules patient data overlay (optional). gantt_include==TRUE, output patchwork object additional Gantt diagram.","code":""},{"path":"https://oncostat.github.io/grstat/reference/boin_plot.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Plot BOIN decision boundaries and patient-level data — boin_plot","text":"","code":"#use a cohort size of 1 boin = BOIN::get.boundary(target=0.3, ncohort=15, cohortsize=1)  #In this example, 17 patients are included, 15 of which are already evaluated. #Patients are deemed evaluable set.seed(123) data_patients = tibble(   subjid = 1:17,   dose = c(\"DL0\", \"DL0\", \"DL-1\", \"DL-1\", \"DL-1\", \"DL0\", \"DL0\", \"DL0\",            \"DL1\", \"DL1\", \"DL1\", \"DL1\", \"DL1\", \"DL1\", \"DL1\", \"DL1\", \"DL1\"),   dlt = c(FALSE, TRUE, FALSE, FALSE, FALSE, FALSE, FALSE, FALSE,           FALSE, FALSE, FALSE, FALSE, TRUE, FALSE, FALSE, NA, NA),   date_dlt_start = as.Date(\"2025-01-01\") +(1:17)*30 + rnorm(17, 0, 10),   date_dlt_end = date_dlt_start+30 )  #default boin_plot(boin,           doses=c(\"DL-1\", \"DL0\", \"DL1\", \"DL2\"))   #with patient labels boin_plot(boin, data_patients=data_patients,           doses=c(\"DL-1\", \"DL0\", \"DL1\", \"DL2\"))   #with gantt diagram p = boin_plot(boin, data_patients=data_patients, gantt_include=TRUE,               doses=c(\"DL-1\", \"DL0\", \"DL1\", \"DL2\")) p   #with post production p[[1]] = p[[1]] + ggplot2::scale_color_manual(values=c(\"red\", \"green\", \"blue\", \"yellow\")) p[[2]] = p[[2]] + ggplot2::scale_x_date(breaks=scales::breaks_width(\"2 months\")) p   #with gantt labels gantt_labels=c(\"Plot cutoff date\"=as.Date(\"2026-06-01\"),                \"Dose reevaluation\"=as.Date(\"2025-04-11\"),                \"Dose reevaluation\"=as.Date(\"2025-07-03\"),                \"Dose reevaluation\"=as.Date(\"2025-09-17\"))  boin_plot(data_boin=boin, data_patients=data_patients,           doses = c(\"DL-2\", \"DL-1\", \"DL0\", \"DL1\"),           gantt_include=TRUE,           gantt_labels=gantt_labels)"},{"path":"https://oncostat.github.io/grstat/reference/butterfly_plot.html","id":null,"dir":"Reference","previous_headings":"","what":"Graphic representation of AEs by CTCAE SOC — butterfly_plot","title":"Graphic representation of AEs by CTCAE SOC — butterfly_plot","text":"Produces graphic representation AEs CTCAE SOC.","code":""},{"path":"https://oncostat.github.io/grstat/reference/butterfly_plot.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Graphic representation of AEs by CTCAE SOC — butterfly_plot","text":"","code":"butterfly_plot(   df_ae,   ...,   df_enrol,   severe = NULL,   sort_by = c(\"total\", \"severe\"),   range_min = NULL,   arm = \"ARM\",   subjid = \"SUBJID\",   soc = \"AESOC\" )  ae_plot_soc(df_ae, ..., df_enrol, severe, sort_by, range_min, arm, subjid, soc)"},{"path":"https://oncostat.github.io/grstat/reference/butterfly_plot.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Graphic representation of AEs by CTCAE SOC — butterfly_plot","text":"df_ae adverse event dataset, one row per AE, containing subjid, soc, grade. ... unused df_enrol enrollment dataset, one row per patient, containing subjid (arm needed). patients dataset. severe name logical column df_ae telling whether AE severe. Case-insensitive. sort_by either \"total\" \"severe\" range_min minimum value upper limit x-axis range. Set 1 always include 100%. arm name treatment column df_enrol. Case-insensitive. Can set NULL. subjid name patient ID df_ae df_enrol. Case-insensitive. soc name SOC column df_ae. Case-insensitive. Grade considered 0 missing (e.g. patient absent df_ae).","code":""},{"path":"https://oncostat.github.io/grstat/reference/butterfly_plot.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Graphic representation of AEs by CTCAE SOC — butterfly_plot","text":"crosstable (dataframe)","code":""},{"path":[]},{"path":"https://oncostat.github.io/grstat/reference/butterfly_plot.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Graphic representation of AEs by CTCAE SOC — butterfly_plot","text":"","code":"tm = grstat_example(N=100) attach(tm, warn.conflicts=FALSE)  ae2 = ae %>%   dplyr::mutate(serious = sae==\"Yes\")  butterfly_plot(ae2, df_enrol=enrolres, range_min=0.5)  butterfly_plot(ae2, df_enrol=head(enrolres,9), range_min=0.5)   ae2 %>%   butterfly_plot(df_enrol=enrolres, severe=\"serious\") +   ggplot2::labs(caption=\"Darker areas represent Serious Adverse Events\")"},{"path":"https://oncostat.github.io/grstat/reference/calc_best_response.html","id":null,"dir":"Reference","previous_headings":"","what":"Calculate Best RECIST Response — calc_best_response","title":"Calculate Best RECIST Response — calc_best_response","text":"Computes best RECIST response per subject based target lesion sum response categories. Ties resolved using lesion sum, date.","code":""},{"path":"https://oncostat.github.io/grstat/reference/calc_best_response.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Calculate Best RECIST Response — calc_best_response","text":"","code":"calc_best_response(   data_recist,   ...,   rc_sum = \"RCTLSUM\",   rc_resp = \"RCRESP\",   rc_date = \"RCDT\",   subjid = \"SUBJID\",   exclude_post_pd = TRUE,   warnings = getOption(\"grstat_best_resp_warnings\", TRUE) )"},{"path":"https://oncostat.github.io/grstat/reference/calc_best_response.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Calculate Best RECIST Response — calc_best_response","text":"data_recist dataset containing longitudinal RECIST data long format. ... used. Ensures named arguments passed. rc_sum column containing sum target lesions. Default \"RCTLSUM\". rc_resp column containing RECIST response (e.g., \"CR\", \"PR\", \"SD\", \"PD\"). Default \"RCRESP\". rc_date column containing assessment date. Default \"RCDT\". subjid column containing subject ID. Default \"SUBJID\". exclude_post_pd Logical; TRUE (default), assessments first PD excluded. warnings Logical; TRUE (default taken getOption(\"grstat_best_resp_warnings\", TRUE)), emits warnings internal checks.","code":""},{"path":"https://oncostat.github.io/grstat/reference/calc_best_response.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Calculate Best RECIST Response — calc_best_response","text":"tibble one row per subject, containing: subjid: Subject ID best_response: best RECIST response observed progression date: date corresponding best response target_sum: Sum target lesions date target_sum_diff_first: Relative difference target sum compared baseline target_sum_diff_min: Relative difference target sum compared minimum observed","code":""},{"path":"https://oncostat.github.io/grstat/reference/calc_best_response.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Calculate Best RECIST Response — calc_best_response","text":"function identifies best response using following logic: Responses ordered: CR > PR > SD > PD > Missing Among best responses, one smallest target lesion sum selected still tied, earliest assessment date selected subjects least two assessments non-missing target sum considered default, assessments first PD excluded (exclude_post_pd = TRUE)","code":""},{"path":"https://oncostat.github.io/grstat/reference/calc_best_response.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Calculate Best RECIST Response — calc_best_response","text":"","code":"db = grstat_example() db$recist %>%   calc_best_response() #> Warning: Function `calc_best_response()` (`?grstat::calc_best_response()`) is not yet #> validated and may produce incorrect results. #> ! Always double-check the results using your own code. #> ℹ Please send your feedback to the grstat team. #> This warning is displayed once every 8 hours. #> Warning: Target Lesions Length Sum is missing at baseline. (2 patients: #72 and #193) #> # A tibble: 199 × 6 #>    subjid best_response       date       target_sum target_sum_diff_first #>     <int> <fct>               <date>          <dbl>                 <dbl> #>  1      1 Complete response   2023-04-16        0                  -1     #>  2      2 Progressive disease 2023-04-23       40.6                 1.33  #>  3      3 Stable disease      2023-05-13       79                   0.122 #>  4      4 Complete response   2023-05-17        0                  -1     #>  5      5 Complete response   2023-07-05        0                  -1     #>  6      6 Complete response   2023-08-31        0                  -1     #>  7      7 Partial response    2023-09-16       50.5                -0.512 #>  8      8 Partial response    2023-09-10       17.9                -0.469 #>  9      9 Partial response    2024-01-12        0                  -1     #> 10     10 Complete response   2024-01-11        0                  -1     #> # ℹ 189 more rows #> # ℹ 1 more variable: target_sum_diff_min <dbl>"},{"path":"https://oncostat.github.io/grstat/reference/check_recist.html","id":null,"dir":"Reference","previous_headings":"","what":"Check a RECIST dataset — check_recist","title":"Check a RECIST dataset — check_recist","text":"Perform multiple checks RECIST dataset. checks can exported HTML Excel report using recist_report_html() recist_report_xlsx().","code":""},{"path":"https://oncostat.github.io/grstat/reference/check_recist.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Check a RECIST dataset — check_recist","text":"","code":"check_recist(rc, mapping = gr_recist_mapping(), exclude_post_pd = TRUE)"},{"path":"https://oncostat.github.io/grstat/reference/check_recist.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Check a RECIST dataset — check_recist","text":"rc recist dataset check mapping character vector defining variable mapping. Refer gr_recist_mapping() default values adjust needed. exclude_post_pd Logical; TRUE (default), assessments first PD excluded.","code":""},{"path":"https://oncostat.github.io/grstat/reference/check_recist.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Check a RECIST dataset — check_recist","text":"tibble nested checks, class check_recist","code":""},{"path":[]},{"path":"https://oncostat.github.io/grstat/reference/check_recist.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Check a RECIST dataset — check_recist","text":"","code":"# we unfortunately cannot provide a flawed simulated recist dataset, at least not yet if (FALSE) { # \\dontrun{ db = read_database() mapping = gr_recist_mapping() recist_check = check_recist(db$rc, mapping=mapping) recist_check recist_report_html(recist_check, title=\"RECIST Check - Study XXX\") recist_report_xlsx(recist_check) } # }"},{"path":"https://oncostat.github.io/grstat/reference/example_ae.html","id":null,"dir":"Reference","previous_headings":"","what":"Generate an Adverse Event table — example_ae","title":"Generate an Adverse Event table — example_ae","text":"Internal function simulates adverse events data toxicity effect depends treatment arm enrolres$arm. effect simulated according enrolres$arm3.","code":""},{"path":"https://oncostat.github.io/grstat/reference/example_ae.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generate an Adverse Event table — example_ae","text":"","code":"example_ae(   enrolres,   seed,   p_na = 0,   p_sae = 0.1,   p_sae_trt = p_sae,   n_max = 15,   n_max_trt = n_max,   w_soc = 1,   w_soc_trt = 1,   beta0 = -1,   beta_trt = 0.4,   beta_sae = 1,   ... )"},{"path":"https://oncostat.github.io/grstat/reference/example_ae.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generate an Adverse Event table — example_ae","text":"enrolres enrolment result table, example_enrol(). seed Integer. Random seed reproducibility (can NULL). p_na proportion missing values (can list value column) p_sae, p_sae_trt proportion serious AE control/exp arms n_max, n_max_trt maximum number AE per patient control/exp arms (binomial probability 20%) w_soc, w_soc_trt log-weights SOC -representated control/exp arms. beta0, beta_trt, beta_sae intercept, treatement coef SAE coef used exponential decay model generates AE grade.","code":""},{"path":"https://oncostat.github.io/grstat/reference/example_ae.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Generate an Adverse Event table — example_ae","text":"tibble N rows following columns: subjid: patient identifier. patient number AE simulated binomial distribution size n_max n_max_trt probability 20%. aesoc: CTCAE System Organ Class. Lazily simulated uniform probability. aeterm: CTCAE High Level Group Term. Lazily simulated uniform probability. Four examples HLGT per SOC provided. aegr: CTCAE grade, ranging 1 5. probability simulated using exponential decay rate grades 1 4 (probs = exp(rate * c(1:4))), probability grade 5 one grade 4 divided 7. probability vector normalized sum 1. rate calculated rate = beta0 + beta_trt*(arm!=\"Control\") + beta_sae*(sae==\"Yes\"). aerel: causality AE. Lazily simulated uniform probability. sae: Indicator Serious AE. Simulated using p_sae p_sae_trt.","code":""},{"path":"https://oncostat.github.io/grstat/reference/example_enrol.html","id":null,"dir":"Reference","previous_headings":"","what":"Generate Example Enrollment Data — example_enrol","title":"Generate Example Enrollment Data — example_enrol","text":"Internal function simulates subject enrollment data random allocation treatment arms inclusion dates.","code":""},{"path":"https://oncostat.github.io/grstat/reference/example_enrol.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Generate Example Enrollment Data — example_enrol","text":"","code":"example_enrol(N, seed, r = 0.5, r2 = 1/3, ...)"},{"path":"https://oncostat.github.io/grstat/reference/example_enrol.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Generate Example Enrollment Data — example_enrol","text":"N Integer. Number subjects simulate. seed Integer. Random seed reproducibility (can NULL). r Numeric. Proportion subjects allocated Control group binary arm variable (default: 0.5). r2 Numeric. Proportion subjects allocated Control group ternary arm3 variable (default: 1/3). ... Additional arguments (currently unused).","code":""},{"path":"https://oncostat.github.io/grstat/reference/example_enrol.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Generate Example Enrollment Data — example_enrol","text":"tibble N rows following columns: subjid: Subject ID arm: Two-arm treatment group (\"Control\" \"Treatment\") arm3: Three-arm treatment group (\"Control\", \"Treatment \", \"Treatment B\") date_inclusion: Inclusion date, spaced 20 days plus uniform jitter","code":""},{"path":"https://oncostat.github.io/grstat/reference/example_rc.html","id":null,"dir":"Reference","previous_headings":"","what":"Simulate a RECIST dataset — example_rc","title":"Simulate a RECIST dataset — example_rc","text":"Internal function simulates synthetic RECIST dataset following conventions clinical oncology trials. simulation, Target Lesions response depends treatment arm enrolres$arm (enrolres$arm3).","code":""},{"path":"https://oncostat.github.io/grstat/reference/example_rc.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Simulate a RECIST dataset — example_rc","text":"","code":"example_rc(   enrolres,   seed,   rc_num_timepoints = 5,   rc_p_new_lesions = 0.09,   rc_p_na = 0.005,   rc_p_nt_lesions_yn = 0.5,   rc_p_nt_lesions_resp = list(CR = 0.73, SD = 0.25, PD = 0.01, NE = 0.01),   rc_sd_tlsum_noise = 0.5,   rc_coef_treatement = 3,   ... )"},{"path":"https://oncostat.github.io/grstat/reference/example_rc.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Simulate a RECIST dataset — example_rc","text":"enrolres enrolment result table, example_enrol(). seed Integer. Random seed reproducibility (can NULL). rc_num_timepoints Integer. Number timepoints patient, including baseline. rc_p_new_lesions Integer. Probability new lesion rc_p_na Integer. Probability missing value reponses Target Lesions, Non-Target Lesions, New Lesions independently. add global response. rc_p_nt_lesions_yn Integer. Probability Non-Target Lesions rc_p_nt_lesions_resp Integer list. Probability Non-Target Lesions response, present rc_sd_tlsum_noise Integer. Standard deviation evolution Target Lesion sum width rc_coef_treatement Integer. Differentiates difference effect control treatment arm (2 arms ). example, rc_coef_treatement = 2 mean growth rate tumor divide per 2 elimination rate multiplied per 2. Also, probability new lesion multiplied 2.","code":""},{"path":"https://oncostat.github.io/grstat/reference/example_rc.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Simulate a RECIST dataset — example_rc","text":"tibble N rows following columns: subjid: patient identifier rcvisit: visit number rcdt: visit date rctlsum: Target Lesion length sum time point. evolution value calculated based percentage variation tumor size previous time point. variation simulated using uniform distribution -30 30, added noise (noise follows normal distribution mean 0 standard deviation rc_sd_tlsum_noise). rctlresp: response associated Target Lesions rcntlresp: response associated Non-Target Lesions rcnew: appearance new lesion rcresp: global RECIST response","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_new_project.html","id":null,"dir":"Reference","previous_headings":"","what":"Create a clinical research project — gr_new_project","title":"Create a clinical research project — gr_new_project","text":"Create clinical research project standardized structure:","code":"├── main.R ├── NEWS.md ├── R │   ├── init.R │   ├── read.R │   ├── check.R │   ├── description.R │   ├── graph.R │   └── report.R ├── README.md └── my_proj.Rproj"},{"path":"https://oncostat.github.io/grstat/reference/gr_new_project.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create a clinical research project — gr_new_project","text":"","code":"gr_new_project(path, open = TRUE, verbose = TRUE)"},{"path":"https://oncostat.github.io/grstat/reference/gr_new_project.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create a clinical research project — gr_new_project","text":"path path. exist, created. open TRUE, opens new project RStudio. verbose TRUE, shows diagnostics.","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_new_project.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create a clinical research project — gr_new_project","text":"path project, invisibly.","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_new_project.html","id":"structure","dir":"Reference","previous_headings":"","what":"Structure","title":"Create a clinical research project — gr_new_project","text":"root project: README.md contains short description project NEWS.md contains descriptions versions project main.R central script sequentially calls others R folder: init.R loads used packages set options read.R reads data sets global variables check.R checks data, e.g. using edc_data_warn() description.R describe data, e.g. using crosstable::crosstable() graph.R create plots, saves disk plots global list report.R creat report, e.g. using officer package","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_new_project.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create a clinical research project — gr_new_project","text":"","code":"if (FALSE) { # \\dontrun{   gr_new_project(\"projects/my_project_folder\") } # }"},{"path":"https://oncostat.github.io/grstat/reference/gr_officer_template.html","id":null,"dir":"Reference","previous_headings":"","what":"GR report template — gr_officer_template","title":"GR report template — gr_officer_template","text":"Create docx template used {officer} standardized report.","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_officer_template.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"GR report template — gr_officer_template","text":"","code":"gr_officer_template(   title,   acronym,   ...,   phase = \"III\",   cset_number = \"CSET20xx/xxx\",   eudract_number = \"20xx-xx\",   ctgov_number = \"xxxxx\",   date_report = \"\",   date_first = \"\",   date_last = \"\",   date_cutoff = \"\",   date_freeze = \"\",   authors = NULL,   sponsor = data.frame(name = \"Gustave Roussy\", address = \"114 Rue Edouard Vaillant\",     code = \"94805 Villejuif Cedex\") )"},{"path":"https://oncostat.github.io/grstat/reference/gr_officer_template.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"GR report template — gr_officer_template","text":"title Study complete title acronym Study acronym ... used. Ensures named arguments passed. phase Study phase cset_number Study CSET identifier eudract_number Study EUDRACT identifier ctgov_number Study identifier clinicaltrial.gov date_report Date report date_first Date first patient inclusion date_last Date last patient inclusion date_cutoff Date analysis cut-date_freeze Date database freeze authors dataframe describing report authors sponsor dataframe describing study's sponsor","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_officer_template.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"GR report template — gr_officer_template","text":"docx object can saved used {officer}","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_officer_template.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"GR report template — gr_officer_template","text":"","code":"authors = dplyr::bind_rows(   c(name=\"Dr Armin Clusion\", role=\"Coordinating investigator\",     address=\"Gustave Roussy\", phone=\"+33\", email=\"name@gustaveroussy.fr\"),   c(name=\"Jeanne Alise \", role=\"Biostatistician\",     address=\"Gustave Roussy, Bureau of Biostatistic and Epidemiology\"),   c(name=\"Bertrand Domise\", role=\"Data-manager\",     address=\"Gustave Roussy, Bureau of Biostatistic and Epidemiology\"),   c(name=\"Arnaud Cébo\", role=\"Pharmacovigilant\",     address=\"Gustave Roussy, Pharmacovigilance Unit\"), ) sponsor = data.frame(name=\"Gustave Roussy\", address=\"114 Rue Edouard Vaillant\",                      code=\"94805 Villejuif Cedex\")  doc = gr_officer_template(   title=\"The Great Study\", acronym=\"TGreStu\",   phase=\"III\",   date_report=\"2025-01-01\",   date_first=\"2024-01-01\",   date_last=\"2024-06-01\",   date_cutoff=\"2024-09-01\",   date_freeze=\"2024-09-01\",   authors = authors,   sponsor = sponsor ) %>%   officer::body_add(\"This is a great study, and here are the stats.\")  path = tempfile(fileext=\".docx\") print(doc, path) browseURL(path)"},{"path":"https://oncostat.github.io/grstat/reference/gr_recist_mapping.html","id":null,"dir":"Reference","previous_headings":"","what":"Default mapping for RECIST dataset — gr_recist_mapping","title":"Default mapping for RECIST dataset — gr_recist_mapping","text":"Generates default mapping RECIST dataset. See sections information columns mandatory.","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_recist_mapping.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Default mapping for RECIST dataset — gr_recist_mapping","text":"","code":"gr_recist_mapping()"},{"path":"https://oncostat.github.io/grstat/reference/gr_recist_mapping.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Default mapping for RECIST dataset — gr_recist_mapping","text":"named character vector","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_recist_mapping.html","id":"mandatory-columns","dir":"Reference","previous_headings":"","what":"Mandatory Columns","title":"Default mapping for RECIST dataset — gr_recist_mapping","text":"columns must present dataset proper RECIST assessment. subjid: Subject ID. rc_date: Date response assessment. target_site: Site target lesion. target_diam: Diameter target lesion. target_resp: Response target lesion. nontarget_yn: Presence (Yes/) non-target lesions. nontarget_resp: Response non-target lesions. new_lesions: Presence new lesions (Yes/). global_resp: Overall response assessment.","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_recist_mapping.html","id":"optional-columns","dir":"Reference","previous_headings":"","what":"Optional Columns","title":"Default mapping for RECIST dataset — gr_recist_mapping","text":"columns used additional checks required. target_is_node: Indicates whether target lesion lymph node. set, inferred based presence substring \"node\" target_site target_method: Imaging method used target lesion assessment. target_sum: Sum diameters target lesions. target_sum_bl: Baseline sum target lesion diameters. target_sum_min: Minimum sum target lesion diameters observed.","code":""},{"path":"https://oncostat.github.io/grstat/reference/gr_recist_mapping.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Default mapping for RECIST dataset — gr_recist_mapping","text":"","code":"gr_recist_mapping() #>         subjid        rc_date    target_site    target_diam    target_resp  #>       \"SUBJID\"         \"RCDT\"     \"RCTLSITE\"     \"RCTLDIAM\"     \"RCTLRESP\"  #>   nontarget_yn nontarget_resp    new_lesions    global_resp target_is_node  #>      \"RCNTLYN\"     \"RCNTLRES\"        \"RCNEW\"       \"RCRESP\"     \"RCTLNODE\"  #>  target_method     target_sum  target_sum_bl target_sum_min  #>      \"RCTLMOD\"      \"RCTLSUM\"       \"RCTLBL\"      \"RCTLMIN\""},{"path":"https://oncostat.github.io/grstat/reference/grstat-package.html","id":null,"dir":"Reference","previous_headings":"","what":"grstat: Clinical Research Tools — grstat-package","title":"grstat: Clinical Research Tools — grstat-package","text":"Gives tools standardize output clinical research description.","code":""},{"path":[]},{"path":"https://oncostat.github.io/grstat/reference/grstat-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"grstat: Clinical Research Tools — grstat-package","text":"Maintainer: Dan Chaltiel dan.chaltiel@gustaveroussy.fr (ORCID) contributors: Team Oncostat (01ed4t417) [copyright holder, funder] Baptiste Archambaud baptiste.archambaud@gustaveroussy.fr [contributor] Charlotte Bargain charlotte.bargain@gustaveroussy.fr [contributor] Aldéric Fraslin alderic.fraslin@gustaveroussy.fr (ORCID) [contributor] Nusaïbah Ibrahimi nusaibah.ibrahimi@gustaveroussy.fr [contributor] Livia Pierotti livia.pierotti@gustaveroussy.fr [contributor]","code":""},{"path":"https://oncostat.github.io/grstat/reference/grstat_example.html","id":null,"dir":"Reference","previous_headings":"","what":"Example databases — grstat_example","title":"Example databases — grstat_example","text":"Example tables, mostly used examples tests.","code":""},{"path":"https://oncostat.github.io/grstat/reference/grstat_example.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Example databases — grstat_example","text":"","code":"grstat_example(N = 200, seed = 42, ...)"},{"path":"https://oncostat.github.io/grstat/reference/grstat_example.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Example databases — grstat_example","text":"N number patients seed random seed (can NULL) ... passed internal functions. See example_enrol(),  example_ae(),  example_rc() argument names.","code":""},{"path":"https://oncostat.github.io/grstat/reference/grstat_example.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Example databases — grstat_example","text":"list datasets, like EDCimport.","code":""},{"path":"https://oncostat.github.io/grstat/reference/rc_check_constancy.html","id":null,"dir":"Reference","previous_headings":"","what":"Target Lesion site and evaluation method should have one value per patient Responses should have one value per date — rc_check_constancy","title":"Target Lesion site and evaluation method should have one value per patient Responses should have one value per date — rc_check_constancy","text":"Target Lesion site evaluation method one value per patient Responses one value per date","code":""},{"path":"https://oncostat.github.io/grstat/reference/rc_check_constancy.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Target Lesion site and evaluation method should have one value per patient Responses should have one value per date — rc_check_constancy","text":"","code":"rc_check_constancy(rc)"},{"path":"https://oncostat.github.io/grstat/reference/rc_check_derived_columns.html","id":null,"dir":"Reference","previous_headings":"","what":"Checks on values calculated in the EDC software Check target sum at any time, at baseline, and at Nadir In TrialMaster, if target_sum is modified, target_sum_bl & target_sum_min are not updated automatically. This also makes duplicates possible. — rc_check_derived_columns","title":"Checks on values calculated in the EDC software Check target sum at any time, at baseline, and at Nadir In TrialMaster, if target_sum is modified, target_sum_bl & target_sum_min are not updated automatically. This also makes duplicates possible. — rc_check_derived_columns","text":"Checks values calculated EDC software Check target sum time, baseline, Nadir TrialMaster, target_sum modified, target_sum_bl & target_sum_min updated automatically. also makes duplicates possible.","code":""},{"path":"https://oncostat.github.io/grstat/reference/rc_check_derived_columns.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Checks on values calculated in the EDC software Check target sum at any time, at baseline, and at Nadir In TrialMaster, if target_sum is modified, target_sum_bl & target_sum_min are not updated automatically. This also makes duplicates possible. — rc_check_derived_columns","text":"","code":"rc_check_derived_columns(rc)"},{"path":"https://oncostat.github.io/grstat/reference/rc_check_global_response.html","id":null,"dir":"Reference","previous_headings":"","what":"Check impossible cases for Target Lesions response — rc_check_global_response","title":"Check impossible cases for Target Lesions response — rc_check_global_response","text":"Check impossible cases Target Lesions response","code":""},{"path":"https://oncostat.github.io/grstat/reference/rc_check_global_response.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Check impossible cases for Target Lesions response — rc_check_global_response","text":"","code":"rc_check_global_response(rc_short)"},{"path":"https://oncostat.github.io/grstat/reference/rc_check_nontarget_response.html","id":null,"dir":"Reference","previous_headings":"","what":"Check impossible cases for Non-Target Lesions response — rc_check_nontarget_response","title":"Check impossible cases for Non-Target Lesions response — rc_check_nontarget_response","text":"Check impossible cases Non-Target Lesions response","code":""},{"path":"https://oncostat.github.io/grstat/reference/rc_check_nontarget_response.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Check impossible cases for Non-Target Lesions response — rc_check_nontarget_response","text":"","code":"rc_check_nontarget_response(rc)"},{"path":"https://oncostat.github.io/grstat/reference/rc_check_target_response.html","id":null,"dir":"Reference","previous_headings":"","what":"Check impossible cases for Target Lesions response — rc_check_target_response","title":"Check impossible cases for Target Lesions response — rc_check_target_response","text":"Check impossible cases Target Lesions response","code":""},{"path":"https://oncostat.github.io/grstat/reference/rc_check_target_response.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Check impossible cases for Target Lesions response — rc_check_target_response","text":"","code":"rc_check_target_response(rc, rc_short)"},{"path":"https://oncostat.github.io/grstat/reference/recist_report_html.html","id":null,"dir":"Reference","previous_headings":"","what":"Create a RECIST check report (HTML or Excel) — recist_report_html","title":"Create a RECIST check report (HTML or Excel) — recist_report_html","text":"Generate report HTML Excel file base RECIST checks made check_recist().","code":""},{"path":"https://oncostat.github.io/grstat/reference/recist_report_html.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Create a RECIST check report (HTML or Excel) — recist_report_html","text":"","code":"recist_report_html(   recist_check,   output_file = \"recist_check.html\",   title = \"RECIST Check\",   open = TRUE )  recist_report_xlsx(   recist_check,   output_file = \"recist_check.xlsx\",   open = TRUE )"},{"path":"https://oncostat.github.io/grstat/reference/recist_report_html.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Create a RECIST check report (HTML or Excel) — recist_report_html","text":"recist_check result check_recist() output_file report file name. title HTML report title. open whether open report afterward.","code":""},{"path":"https://oncostat.github.io/grstat/reference/recist_report_html.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Create a RECIST check report (HTML or Excel) — recist_report_html","text":"output_file invisibly. Called side effects.","code":""},{"path":"https://oncostat.github.io/grstat/reference/recist_report_html.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Create a RECIST check report (HTML or Excel) — recist_report_html","text":"","code":"# we unfortunately cannot provide a flawed simulated recist dataset, at least not yet if (FALSE) { # \\dontrun{ db = read_database() mapping = gr_recist_mapping() recist_check = check_recist(db$rc, mapping=mapping) recist_check recist_report_html(recist_check, title=\"RECIST Check - Study XXX\") recist_report_xlsx(recist_check) } # }"},{"path":"https://oncostat.github.io/grstat/reference/reexports.html","id":null,"dir":"Reference","previous_headings":"","what":"Objects exported from other packages — reexports","title":"Objects exported from other packages — reexports","text":"objects imported packages. Follow links see documentation. dplyr %>% flextable as_flextable tibble tibble","code":""},{"path":"https://oncostat.github.io/grstat/reference/survfit_stack.html","id":null,"dir":"Reference","previous_headings":"","what":"Stack multiple survival endpoints into a single survfit2 object — survfit_stack","title":"Stack multiple survival endpoints into a single survfit2 object — survfit_stack","text":"function combines several survival endpoints dataset stacking long format fitting single survfit object. support competing risks models (.e., event variable factor).","code":""},{"path":"https://oncostat.github.io/grstat/reference/survfit_stack.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Stack multiple survival endpoints into a single survfit2 object — survfit_stack","text":"","code":"survfit_stack(data, surv_list)"},{"path":"https://oncostat.github.io/grstat/reference/survfit_stack.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Stack multiple survival endpoints into a single survfit2 object — survfit_stack","text":"data data frame containing survival variables. surv_list named list element character vector : Length 2: time, event (standard right-censored survival) Length 3: time1, time2, event (interval-censored survival left truncation) names list elements used grouping variable output.","code":""},{"path":"https://oncostat.github.io/grstat/reference/survfit_stack.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Stack multiple survival endpoints into a single survfit2 object — survfit_stack","text":"survfit object (survfit2 ggsurvfit installed)","code":""},{"path":"https://oncostat.github.io/grstat/reference/survfit_stack.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Stack multiple survival endpoints into a single survfit2 object — survfit_stack","text":"","code":"library(dplyr) #>  #> Attaching package: ‘dplyr’ #> The following objects are masked from ‘package:stats’: #>  #>     filter, lag #> The following objects are masked from ‘package:base’: #>  #>     intersect, setdiff, setequal, union set.seed(42) df_surv = survival::lung %>%   as_tibble() %>%   mutate(     time_os = time,     event_os = status == 2,     time_pfs = time / (1 + runif(n())),     event_pfs = ifelse(runif(n()) > 0.3, event_os, 1),     time_efs = time_pfs / (1 + runif(n())),     event_efs = ifelse(runif(n()) > 0.3, event_pfs, 1)   )  surv_list = list(   \"Overall survival\" = c(\"time_os\", \"event_os\"),   \"Progression-free survival\" = c(\"time_pfs\", \"event_pfs\"),   \"Event-free survival\" = c(\"time_efs\", \"event_efs\") )  if(require(\"ggsurvfit\")){    df_surv %>%     survfit_stack(surv_list=surv_list) %>%     ggsurvfit() +     add_confidence_interval() +     add_risktable() +     scale_ggsurvfit()  } #> Loading required package: ggsurvfit #> Loading required package: ggplot2 #> Warning: Function `survfit_stack()` (`?grstat::survfit_stack()`) is not yet validated #> and may produce incorrect results. #> ! Always double-check the results using your own code. #> ℹ Please send your feedback to the grstat team. #> This warning is displayed once every 8 hours."},{"path":"https://oncostat.github.io/grstat/reference/waterfall_plot.html","id":null,"dir":"Reference","previous_headings":"","what":"Waterfall plot for RECIST data — waterfall_plot","title":"Waterfall plot for RECIST data — waterfall_plot","text":"Creates waterfall plot showing change baseline target lesion size individual patients, optionally grouped treatment arm.","code":""},{"path":"https://oncostat.github.io/grstat/reference/waterfall_plot.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Waterfall plot for RECIST data — waterfall_plot","text":"","code":"waterfall_plot(   data,   ...,   y = \"target_sum_diff_first\",   fill = \"best_response\",   shape = NULL,   arm = NULL,   subjid = \"SUBJID\",   resp_colors = c(CR = \"#42b540\", PR = \"#006dd8\", SD = \"#925e9f\", PD = \"#ed0000\", `NA` =     \"white\"),   warnings = getOption(\"grstat_wp_warnings\", TRUE) )"},{"path":"https://oncostat.github.io/grstat/reference/waterfall_plot.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Waterfall plot for RECIST data — waterfall_plot","text":"data dataset containing RECIST best response data. Use calc_best_response format raw data. ... used. Ensures named arguments passed. y column representing numeric outcome (typically change tumor size). Default \"target_sum_diff_first\". fill column indicating filling color. Default \"best_response\", best response category. shape column use shape layer (e.g., indicating mutation status). arm column indicating treatment arms faceting. subjid column identifying subjects. Default \"SUBJID\". resp_colors Colors assigned response categories. warnings Whether display warnings.","code":""},{"path":"https://oncostat.github.io/grstat/reference/waterfall_plot.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Waterfall plot for RECIST data — waterfall_plot","text":"ggplot object representing waterfall plot tumor size change patient.","code":""},{"path":"https://oncostat.github.io/grstat/reference/waterfall_plot.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Waterfall plot for RECIST data — waterfall_plot","text":"","code":"db = grstat_example(N=50) data_best_resp = calc_best_response(db$recist)  #simple example waterfall_plot(data_best_resp)   #facet by arm data_best_resp %>%   dplyr::left_join(db$enrolres, by=\"subjid\") %>%   waterfall_plot(arm=\"ARM\")    #add symbols #use the NA level to not show the case set.seed(0) data_symbols = db$recist %>%   dplyr::summarise(     new_lesion=ifelse(any(rcnew==\"Yes\", na.rm=TRUE), \"New lesion\", NA),     example_event=cut(runif(1), breaks=c(0,0.05,0.1,1), labels=c(\"A\", \"B\", NA)),     .by=subjid   )  data_best_resp %>%   dplyr::left_join(data_symbols, by=\"subjid\") %>%   waterfall_plot(shape=\"new_lesion\")   data_best_resp %>%   dplyr::left_join(data_symbols, by=\"subjid\") %>%   waterfall_plot(shape=\"example_event\") +   ggplot2::labs(shape=\"Event\")"},{"path":[]},{"path":"https://oncostat.github.io/grstat/news/index.html","id":"new-features-0-1-0","dir":"Changelog","previous_headings":"","what":"New features","title":"grstat 0.1.0 (development version)","text":"Adverse events description tables: ae_table_grade() ae_table_soc() Adverse events description plots: ae_plot_grade(), ae_plot_grade_sum() butterfly_plot() (aka ae_plot_soc())","code":""}]
